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“It is good to have an end to journey toward; but it is the 
journey that matters, in the end.” 
 
 
― Ernest Hemingway 
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1. Abbreviations 
 
2PM    two-photon microscopy 
AAV   Adeno-assosciated virus 
AD   Alzheimer`s disease 
ADL   activities of daily living 
APOE   apolipoprotein E 
APP   amyloid precursor protein 
Aβ   amyloid-beta 
BAPTA  1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
BBB   blood brain barrier 
BOLD   blood oxygenation level-dependent 
CAA   cerebral amyloid angiopathy 
CaCl2   calcium chloride 
CAG   chicken β-actin 
CFP   cyan fluorescent protein 
CR   complement receptor 
CSF   cerebrospinal fluid 
CT   computed tomography 
CX3CR1  fractalkine receptor 
DMSO   dimethyl sulfoxide 
DNA   deoxy nucleic acid 
EAE   expreimental autoimmune encephalomyelitis 
EEG   electro encephalogram 
EOFAD  early onset familial Alzheimer`s disease 
fMRI   functional magnetic resonance imaging 
FRET   fluorescent resonant energy transfer 
FTD   frontotemporal dementia 
GABA   gamma amino butyric acid 
GECI   genetically encoded calcium indicators 
GFP   green fluorescent protein 
GSK   glycogen synthase kinase 
i.p.   intra peritoneal 
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i.v.   intra venous 
IL   interleukin 
IR   infra-red 
ISI   intrinsic signal imaging 
KCl   potassium chloride 
LBD   Lewy body dementia 
LOAD   late onset Alzheimer`s disease 
LTD   long term depression 
LTP   long term potentiation 
MAPK   mitogen-activated protein kinase 
MHC   major histocompatiblity complex 
MHz   mega Hertz 
MMSE  mini-mental state examination 
MRI   magnetic resonance imaging 
NA   numerical aperture 
nAChR  nicotine acetyl choline receptor 
NaCl   sodium chloride 
NaOH   sodium hydroxide 
NFT   neurofibrillary tangles 
NMDAR  N-methyl-D-aspartate receptor 
NRR   normal rat ringer 
NSAID  non –steroidal anti-inflammatory drugs 
OGB   Oregon green BAPTA-1 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PET   positron emission tomography 
PFA   paraformaldehyde 
PHF   paired helical filaments 
PiB   Pittsburg compound B 
PPARγ  Peroxisome proliferator-activated receptor gamma 
PSEN   presenelin 
ROI   region of interest 
RT   room temperature 
s.c.   subcutaneous 
Abbreviations 
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SD   standard deviation 
SR 101  sulforhodamine  
SR   scavenger receptor 
TBS   tris-buffered saline 
TGF   transforming growth factor 
TLR   Toll-like receptor 
TNF   tumor necrosis factor 
VPM   ventral posterior medical nucleus 
YC   yellow cameleon 
YFP   yellow fluorescent protein 
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2. Summary/Zusammenfassung 
As life expectancy of humans is increasing all over the world, incidence of age-
related diseases is increasing as well.  One amongst them is Alzheimer’s disease 
(AD), a multifactorial neurodegenerative disease, which is characterized by cognitive 
deficits, memory loss and personality changes. Histopathology of AD affected brains 
show abnormal accumulation and aggregation of the amyloid β (Aβ) peptide forming 
Aβ plaques and hyperphosphorylation of the neuronal tau protein resulting in the 
formation of neurofibrillary tangles, both of which are considered histopathological 
hallmarks of AD. Aβ, which can exist in various forms from soluble monomers to 
insoluble fibrils is presumed to be the main culprit in causing neuronal dysfunction.  
 
The options for medical management of AD are very limited. There are only four 
FDA approved drugs available in the market, all of which are only palliative. 
Numerous molecular and drug targets have been identified over last decade thus 
making AD therapeutics an interesting field. The forerunner amongst various 
therapies is immunotherapy with anti-Aβ antibodies, which has been successful in 
animal models and currently undergoing large multi-center clinical trials.  
 
The mechanism of neuronal dysfunction in AD yet remains to be completely 
understood. Technical and molecular advances such as two-photon microscopy (2PM) 
and genetically encoded calcium indicators are making it easier to answer these 
questions in an in vivo setting, more so in AD transgenic mice models. However, 
these approaches are technically very challenging. The first step towards chronic 
imaging was standardization of protocols. We used the standardization technique to 
look at morphological aspects of beta-amyloid plaque and microglia interaction in 
transgenic mice with GFP expressing microglia. Local application of anti-Aß 
antibodies was done and time-lapse imaging of microglia surrounding plaques was 
carried out to standardize operating and imaging protocols. 
 
We then combined the techniques of chronic in vivo imaging, 2PM and genetically 
encoded calcium indicators to study sensory-evoked response of neurons in 
somatosensory cortex of living mice over a period of weeks in the context of pre-
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plaque AD pathology. Furthermore, we passively immunized the mice with an in-
house generated anti-Aβ antibody targeted against fibrillar Aβ to study neuronal 
responses before and after immunization. We were able to image the same population 
of cells over a period of time in wild type and AD transgenic mice. AD transgenic 
mice showed a trend towards having lower neuronal activity compared to wild type 
mice. Passive immunotherapy showed a promising trend towards improvement of 
some components of neuronal activity such as spontaneous response.  Our results 
show that longitudinal imaging of neuronal ensembles in AD is now achievable and 
these chronic imaging protocols can be used to study therapeutics. This opens new 
opportunities in terms of studying AD pathophysiology starting from disease onset 
and follow the progression of neurodegeneration and monitor efficacy of treatment 
agents. 
 
Overall, this dissertation was successful in establishing chronic imaging protocols and 
test them in pre-plaque AD mice, thus proving that chronic imaging of neuronal 
activity is possible in AD animal models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary/Zusammenfasung 	  
	  	   13	  
Zusammenfassung 
Mit der weltweit ansteigenden Lebenserwartung, steigt auch die Anzahl 
altersbedingter Erkrankungen. Die häufigste ist die Alzheimer Demenz (AD), eine 
multifaktorielle neurodegenerative Erkrankung, welche durch kognitive Defizite, 
Gedächtnisdefizite und Veränderungen der Persönlichkeit gekennzeichnet ist. 
Histopathologisch findet man in AD Hirnen eine abnormale Anhäufung und 
Aggregation des Aβ-Peptids, welches in Plaques akkumuliert, sowie eine 
Hyperphosphorylierung des neuronalen Tau Proteins, das zur Bildung neurofibrillärer 
Tangles führt. Beide gelten als sichere histopathologische postmortem Kriterien für 
AD.  
Es wird vermutet, dass Aβ, welches in verschiedensten Spezies, von löslichen 
Monomeren bis hin zu unlöslichen Fibrillen existiert, die Ursache der Demenz und 
der neuronalen Dysfunktionen darstellt. 
 
Die Möglichkeiten einer Therapie für AD sind kaum vorhanden. Es existieren nur vier 
FDA zugelassene Medikamente, die alle palliativ eingesetzt wirken. Es wurden 
zahlreiche molekulare Ansätze analysiert und mögliche Pharmakotherapien 
vorgeschlagen. 
Der vielversprechendste Ansatz hier ist eine Immuntherapie mit anti- Aβ-gerichteten 
Antikörpern, die bereits Erfolge in AD-Tiermodellen gezeigt haben und im Moment 
grosse multizentrische klinische Studien durchlaufen. 
 
Die Mechanismen hinter der neuronalen Dysfunktion in AD sind jedoch noch nicht 
vollständig aufgeklärt.  
Moderne Technologien, wie die Zwei-Photonen-Mikroskopie (2PM), und genetisch 
codierte Kalzium Indikatoren erleichtern es, diese Fragen in einem in vivo transgenen 
Mausmodell näher zu erörtern. Diese Ansätze sind technisch aber sehr anspruchsvoll. 
Der erste Schritt bei der Etablierung der chronischen Bildgebung ist die 
Standardisierung von Methoden-Protokollen. Wir verwendeten diese 
Standardisierungstechnik, um morphologische Aspekte der Interaktion zwischen beta-
amyloid Plaques und GFP-markierten Microglia in transgenen Mäusen zu 
analysieren. Es erfolgte eine lokale Applikation von anti- Aß-gerichteten Antikörpern, 
um durch eine Zeitraffer Bildgebung von Plaques, die von Microglia umgeben waren, 
Summary/Zusammenfasung 
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Aufnahmen machen zu können, denen standardisierte Protokolle zugrunde liegen.  
 
Wir haben daraufhin die Techniken der Langzeit in vivo-Bildgebung, 2PM und 
genetisch kodierten Kalzium-­‐Indikatoren miteinander kombiniert, um sensorisch	  ausgelöste	  Potentiale der Neuronen im somatosensorischen Kortex lebender Mäuse 
über einen Zeitraum von mehreren Wochen im Rahmen der Prä-­‐Plaque-­‐AD-
Pathologie zu studieren. Darüber hinaus wurden die Mäuse mit einem	   selbst	  
generierten anti-Aß-Antikörper, der gegen Aß-­‐Fibrillen gerichtet ist, passiv 
immunisiert, um die Folgen für betroffene Neuronen vor und nach der Immunisierung 
untersuchen zu können. Der Vorteil der chronischen Bildgebung liegt darin, dass man 
die gleiche Population von Zellen über einen längeren Zeitraum hinweg aufnehmen 
kann. Transgene AD Mäusen zeigten im Vergleich zu Wildtyp-Mäusen die Tendenz 
zu verlangsamter neuronaler Aktivität. Die passive Immunisierung ist ein 
vielversprechender Ansatz zur Verbesserung der neuronalen Aktivität, so z.B. der 
Spontanaktivität der Neuronen. Unsere Ergebnisse zeigen, dass die Langzeit-­‐
Bildgebung neuronaler Netzwerke in AD darstellbar wird und dass die etablierten 
Protokolle verwendet werden können, um Therapeutika besser zu studieren. Dies 
eröffnet neue Möglichkeiten die AD Pathophysiologie zu erforschen, von Beginn der 
Krankheit bis hin zur Neurodegeneration und ermöglicht das Ueberwachen des 
Therapieerfolgs.	  
 
Abschliessend war diese Dissertation erfolgreich in der Etablierung von Langzeit-
Bildgebungs- protokollen und der Erprobung dieser Protokolle in Prä-Plaque AD 
Mausmodellen, die nun dafür eingesetzt werden können, neuronale Aktivität in 
Tiermodellen zu manipulieren und darzustellen.  
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3.1 Alzheimer’s Disease 	  
‘Our memories define who we are’ says psychologist Howard Eichenbaum. This 
couldn’t have been more relevant in the case of Alzheimer’s disease (AD) patients, 
who suffer from memory loss and cognitive deficits, which ultimately lead to 
personality changes. AD is the most common form of dementia and fourth in the list 
of leading causes of death in industrialized societies, preceded only by heart disease, 
cancer, and stroke (Carter, et al. 2010) and is on the rise in the developing countries 
too (World Alzheimer Report 2011).  
 
3.1.1 Prevalence and risk factors 
AD constitutes about 70% of all dementia cases (Castellani, et al. 2010). Incidence of 
AD increases with age, doubling every 5-10 years. For persons between ages 65 and 
69, 70 and 74, 75 and 79, 80 and 84, and 85 and older the incidence of AD has been 
estimated to be 0.6%, 1.0%, 2.0%, 3.3%, and 8.4% respectively (Fratiglioni, et al. 
1999, Small, et al. 1997). Prevalence also increases exponentially with age, rising 
from 3% among those 65-74 to almost 50% among those 85 or older (Hebert, et al. 
1995). In 2010, there were 35.6 million cases of Alzheimer’s disease in the world  
(Brookmeyer, et al. 2007). It is predicted that by the year 2050, the worldwide 
prevalence of Alzheimer’s will grow fourfold, to 106.8 million with 1 in 85 persons 
living with AD (Brookmeyer, et al. 2007). The above data are in keeping in mind the 
projected demographic changes resulting from the ‘baby boomer’ generation reaching 
old age and the continued increase in life expectancy (Castellani, et al. 2010). The 
total estimated worldwide costs of dementia were US$604 billion in 2010. These 
costs account for around 1% of the world’s gross domestic product, varying from 
0.24% in low income countries, to 0.35% in low middle income countries, 0.50% in 
high middle income countries, and 1.24% in high income countries (World Alzheimer 
Report 2011). 
 
Conventionally, AD is genetically divided into two forms (Bertram, et al. 2010): (1) 
familial cases with Mendelian inheritance of predominantly early-onset (<60 years, 
early-onset familial AD [EOFAD]), and (2) so-called ‘sporadic cases’ with less 
Introduction 	  
	   18	  
apparent or no familial aggregation and usually of later onset age (≥60 years, late-
onset AD [LOAD]). This traditional dichotomization is overly simplistic as there are 
cases of early-onset AD without evidence for Mendelian transmission while, 
conversely, LOAD is frequently observed with a strong familial clustering, sometimes 
resembling a Mendelian pattern. While EOFAD is caused by rare and highly 
penetrant mutations in three genes; amyloid precursor protein (APP) (Figure 3.1), 
Presenilin-1 (PSEN1) and Presenilin-2 (PSEN2), the genetics of LOAD is more 
complex. The current hypothesis is that susceptibility for LOAD is conferred by 
numerous genetic risk factors of relatively high frequency but low penetrance and 
therefore small effect size. While LOAD is also sometimes referred to as ‘sporadic 
AD’, it is important to emphasize that up to 60%–80% of this form of AD is 
genetically determined (Bertram, et al. 2010, Gatz, et al. 2006). Most of the APP 
mutations can be found in close proximity to or at the proteolytic cleavage sites at 
which APP is processed by its secretases (Figure 3.1). Notably, not all APP mutations 
lead to the same symptoms or do not even result in the EOFAD phenotype: for 
example, the E693Q Dutch mutation causes hereditary cerebral hemorrhage with 
amyloidosis (HCHWA-D) resulting in severe intracerebral bleedings and cerebral 
amyloid angiopathy (CAA) (Maat-Schieman, et al. 2005); the E693K mutation, 
however, causes exclusively CAA without AD-type dementia (Bugiani 2004), 
whereas the arctic mutation (E693G) shows a clear AD phenotype with both neuritic 
plaques and extensive CAA (Watson, et al. 1999).  
 
Another line of evidence supporting the role of APP in AD pathology is the early 
plaque deposition and development of behavioral deficits and cognitive impairment 
typical of AD in people with Down’s syndrome, which is caused by chronic over 
production of Aß resulting from triplication of chromosome 21 (Lemere, et al. 1996). 
 
Another factor, which predisposes to AD, is the presence of apoliopoprotein E ε4 
(APOE ε4) allele. As compared to individuals with no ε4 alleles, the increased risk for 
AD is 2- to 3- fold in people with one ε4 allele and about 12-fold in those with 2 ε4 
alleles (Bertram and Tanzi 2009, Roses 1996). The APOE ε4 allele is also associated 
with an earlier age of AD onset (Meyer, et al. 1998, Raber, et al. 2004).  
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It is important to note that the ε2 allele of APOE is associated with a lower risk for 
AD (Corder, et al. 1993, Farrer, et al. 1997).  However, it is difficult to define whether 
the APOE ε4 allele represents a gain of toxic function, a loss of neuroprotective 
function, or both (Kim, et al. 2009). 
  
Still, environmental and epigenetic factors also make an important contribution in 
determining an individual’s risk, although the precise nature and mechanisms 
underlying these non-genetic components remain largely undetermined, mainly 
because they are difficult to assess experimentally (Bertram and Tanzi 2009, Traynor 
and Singleton 2010). 
 
 
       
 
Figure 3.1: APP mutations in 
FAD. Part of the APP amino-
sequence; mutations associated have 
been highlighted. The mutations are 
named after nationality or the 
location of the first family in which 
the specific mutation was 
demonstrated. It is important to note 
that most mutations are in the 
vicinity of secretase-cleaving sites, 
which influences APP processing. 
The Aβ sequence is indicated in red. 
(Image adapted from Van Dam 
2006).  
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3.1.2 Clinical features 
AD was first described as ‘eigenartige Erkrankung der Hirnrinde’ by Bavarian 
psychiatrist Alois Alzheimer in 1906 based on clinical findings and autopsy results of 
his 51-year-old patient Ms. August Deter. It was Emil Kraepelin who later named it as 
Alzheimer’s disease (Alzheimer, et al. 1995). 
 
The clinical disease stages are preceded by many years of prodromal AD, initially 
announced by mild cognitive impairment (MCI) that gradually progresses from subtle 
cognitive and memory problems such as word finding difficulty and decreased 
organization capacity to severe deficits such as inability to perform activities of daily 
living (ADLs), inevitably ending in severe dementia (Figure 3.2). The composite 
clinical picture at any stage is variable among AD patients, including cognitive and 
memory problems, and mild to severe changes in social behavior with mood swings 
and altered personality and character, including apathy, depression, irritability, 
agitation, psychosis and aggression (Blennow, et al. 2006). 
 
 
 
The diagnosis of AD requires clinical evidence of memory loss and impairment of at 
least one other cognitive domain, with evidence of disturbance in social or 
occupational function. AD must be differentiated from other causes of dementia 
namely, vascular dementia, frontotemporal dementia (FTD), dementia with Lewy 
body (LBD), Parkinson’s disease with dementia to name a few.  
Figure 3.2: 
Clinical course of 
AD. The clinical 
features are 
insidious in onset 
and gradually 
progress over 
years. Adapted 
from Gauthier 
1996 (image from 
EPG health media) 
Y-axis is MMSE 
score which is a 
neuropsychological 
test and highest 
score is 30.  
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The major criteria for diagnosis of AD are defined by DSM-IV and National Institute 
of Neurological Disorders and Stroke-Alzheimer Disease and Related Disorders 
(NINCDS-ADRDA) (Dubois, et al. 2007, McKhann, et al. 1984) (Figure 3.3).  
 
 
 
The medical history together with clinical, neurological and psychiatric examination 
serve as the basis in the diagnostic work-up. In very early cases, neuropsychological 
testing (such as mini-mental scale examination; MMSE) can help to obtain objective 
signs of memory disturbances (Blennow, et al. 2006). Neuroimaging (CT and MRI), 
plays an important part in the diagnosis of AD and the imaging usually shows diffuse 
or anteriorly predominant cortical and hippocampal atrophy. Positron emission 
tomography (PET) imaging of glucose metabolism and Aβ deposits by using 
Pittsburg compound B (PiB) and CSF biomarkers (Aβ 1-40 and 1-42, total and 
phospho tau) are also useful. Laboratory studies such as thyroid function tests and 
serum vitamin B12 are done to rule out secondary causes of dementia (Blennow, et al. 
2006). A definitive diagnosis of AD can only be made by neuropathology, which is 
regarded as gold standard (McKhann, et al. 1984). 	  	  
Figure 3.3: NINCDS-ADRDA criteria for Alzheimer’s disease. The table is adapted from 
Castellani et al. 2010 
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3.1.3 Neuropathology 	  
Gross pathology 
Classically, the brains of individuals with AD are atrophic with widened sulci, 
narrowed gyri and dilated ventricles (hydrocephalus ex vacuo) (Figure 3.4). The 
neurodegenerative process in AD probably initiates in the entorhinal cortex and the 
frontal cortex and disseminates to the hippocampus (Braak and Braak 1996) and other 
neocortical regions such as temporal, parietal and cingulate regions (Minoshima, et al. 
1994). However, atrophy is mostly absent in the cerebellum and brain stem regions  
(Perl 2010). 
 
  
 
 
Histopathology 
The most common and distinctive ‘hallmark’ lesions present within the AD brain are 
the senile plaques and neurofibrillary tangles (NFTs).  
 
Senile plaques are complex, extracellular deposits composed primarily of amyloid-β, 
a 4 kDa β-pleated sheet structured peptide. The predominant beta-pleated sheet 
configuration of this protein confers its ability to bind the planar dye Congo red and 
produce birefringence when illuminated by polarized light; it thus conforms to the 
Figure 3.4: Comparison between brains of AD patient and healthy control Left: brain of a 
healthy control Right: brain of AD patient, showing generalized atrophy, ventricular dilation, 
widening of sulci and narrowed gyri. (Image from Alzheimer's Disease Education and Referral 
Center, a service of the National Institute on Aging). 
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physical definition of an amyloid (Perl 2010). The nosology of senile plaque has 
evolved over the years to include multiple plaque subtypes, including primitive, 
neuritic, compact, cored, cotton-wool and vascular (Castellani, et al. 2010). The 
neuritic plaque (Figure 3.5A) in particular has been touted to be the most 
pathogenically relevant and often highlighted as the plaque of significance. The 
neuritic plaques are thus called because of the dystrophic neurites, which surround 
them and show signs of neuroinflammation, such as activated microglia and 
astrogliosis. The vascular Aβ deposits, termed as cerebral amyloid angiopathy (CAA), 
affect medium and small-sized leptomenigeal and cortical arteries and arterioles and 
less frequently capillaries and veins (Rensink, et al. 2003). Microscopically, CAA 
consists of deposition of Aβ in the smooth muscle layer (tunica media) of the vessel 
wall. CAA leads to focal fragmentation of blood brain barrier and leakage.  
 
NFTs are intraneuronal accumulation of hyperphosphorylated of microtubule-
associated protein tau. NFTs are observed as abnormal fibrous inclusion bodies 
appearing as paired helical filaments (PHFs) within the neuronal cytoplasm in the 
brains of AD patients (Figure 3.5B). Most of these NFTs are found in the entorhinal 
cortex, amygdala, hippocampus and neocortex  (Morrison and Hof 1997). Following 
neuronal death, NFTs remain extracellularly in the neuropil as ghost tangles. 
 
 
Figure 3.5: Plaque and NFT. (A) Senile plaque demonstrated by Bielshowsky silver 
impregnation (B) Neurofibrillary tangle as seen on Bielshowsky silver stain. Both images are 
adapted from Casetllani et al. 2010.  
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Apart from plaques and tangles, other histopatholigcal findings of the AD brain are 
neuronal and dendritic loss, neuropil threads, dystrophic neurites, granulovascular 
degenration and Hirano (Castellani, et al. 2010). The common refrain ‘synapse loss is 
the most specific pathologic feature of AD’ is now an accepted dogma, which is based 
on accumulating evidence associating synapse loss with soluble Aβ species 
(Castellani, et al. 2010). Even with the wealth of information available, the complete 
mechanism of neurodegenration is yet to understood. 
 
3.1.4 Neuronal dysfunction in AD 
There has been a paradigm shift over the last few years as to the mechanisms of 
neurodegeneration in AD. The original idea was that beta-amyloid plaque is the main 
neurotoxic species causing neuronal dysfunction, which was proposed by Hardy and 
Higgins in 1992 (Hardy and Higgins 1992). It is now known that Aβ can exist in 
diverse assembly states, including monomers, dimers, trimers, tetramers, dodecamers, 
high-order oligomers and protofibrils, as well as mature fibrils, which can form 
microscopically visible amyloid plaque in brain tissues (Glabe 2008). Much evidence 
suggests that Aβ oligomers are more potent than Aβ fibrils and amyloid deposits in 
eliciting abnormalities in synaptic functions and neural network activity (Cheng, et al. 
2007, Cleary, et al. 2005, Klein, et al. 2001, Lesne, et al. 2006, Palop and Mucke 
2010, Selkoe 2008, Shankar, et al. 2007, Shankar, et al. 2008, Tomiyama, et al. 2010, 
Walsh and Selkoe 2007). This has led to the revision of the original amyloid cascade 
hypothesis (Blennow, et al. 2006, Hardy and Selkoe 2002) (Figure 3.6). 
 
Recent findings indicate that Aβ is part of an activity regulated mechanism that 
controls synaptic excitatory activation, in which Aβ induces presynaptic facilitation at 
low concentration and postsynaptic depression at high concentrations (Palop and 
Mucke 2010). Pathologically elevated Aβ may indirectly cause a partial block of 
NMDARs and shift the activation of NMDAR-dependent signaling cascades toward 
pathways involved in the induction of LTD and synaptic loss (Hsieh, et al. 2006, 
Kamenetz, et al. 2003, Shankar, et al. 2007).  
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Although the mechanisms underlying Aβ-induced LTD have not yet been fully 
elucidated, they may involve receptor internalization (Hsieh, et al. 2006, Snyder, et al. 
2005) or desensitization (Liu, et al. 2004) and subsequent collapse of dendritic spines 
(Hsieh, et al. 2006, Snyder, et al. 2005). Aβ-dependent effects on synaptic function 
may be mediated by activation of α7-nAChR (Snyder, et al. 2005), perisynaptic 
activation of NMDARs  (Li, et al. 2009, Shankar, et al. 2007) and downstream effects 
on calcineurin–STEP–cofilin, p38 MAPK and GSK-3β signaling pathways (Li, et al. 
2009, Shankar, et al. 2007, Tackenberg and Brandt 2009, Wang, et al. 2004) 
 
Aβ also causes GABAergic dysfunction, which may contribute to the development of 
aberrant synchrony in neural networks and disruption of cognitive function (Palop and 
Mucke 2010). It is known that increased neuronal activity increases Aβ production 
and blocking neuronal activity has the opposite effect (Kamenetz, et al. 2003). Several 
recent reports in AD mouse models suggest that pathologically elevated Aβ 
Figure 3.6: Revised amyloid cascade hypothesis. Sequential events in familial and sporadic AD that 
could ultimately lead to symptoms of dementia (adapted from Blennow, et al. 2006).  
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destabilizes neuronal activity at network levels (Palop and Mucke 2010). Defects in 
LTP are seen much before the appearance of plaques (Knobloch, et al. 2007a). In vivo 
calcium imaging of cortical circuits shows that APP/PS1 mice have a greater 
proportion of hyperactive and hypoactive neurons than nontransgenic controls  
(Busche, et al. 2008). Notably, these AD mouse models have reduced glutamatergic 
excitatory currents and synaptic loss, suggesting that high Aβ leads to aberrant 
patterns of neuronal activity by enhancing synchrony among the remaining 
glutamatergic synapses rather than by increasing excitatory synaptic activity per se  
(Palop and Mucke 2010). Emerging evidence also suggests that GABAergic 
dysfunction may be key in the pathogenesis of network dysfunction in AD. Important 
clues came from the demonstration of hyperactive and hypoactive neurons in cortical 
circuits of APP/PS1 mice, which point towards change of biophysics between 
excitatory and inhibitory neurons (Busche, et al. 2008, Grienberger, et al. 2012). 
 
Different approaches which have been used to address the question of neuronal 
dysfunction in AD, ranging from non-invasive techniques such as electro-
encephalogram (EEG) and fMRI in animals to invasive techniques such as 
extracellular recordings, calcium imaging in cells and slice cultures. Even though 
these techniques have provided a good understanding of the synaptic activity, not 
much is really known about the temporal alterations in neuronal activity and disease 
progression. Most recently Li et al. 2011 showed in cell culture model that soluble Aβ 
oligomers from three distinct sources (cultured cells, AD cortex, or synthetic peptide) 
inhibited LTP, and this was prevented by the selective NR2B inhibitors ifenprodil and 
Ro25-6981. Soluble Aβ enhanced NR2B-mediated NMDA currents and extrasynaptic 
responses. More in vivo studies addressing the issue of the relationship between Aβ-
induced alterations at the level of circuits and networks are required.  
 
3.1.5 Mouse models of AD 
A number of transgenic mice have been created over the last two decades that 
overexpress APP and/or presenilin containing one or more mutations linked to 
familial AD. These mice recapitulate many key aspects of AD, including amyloid 
neuropathology, cerebral amyloid angiopathy, synaptic loss, dystrophic neurites, and 
reactive gliosis, as well as impairments in synaptic plasticity and learning and 
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memory. Such mouse models exhibit these characteristics to varying extents, and are 
widely used to investigate the roles of APP, Aβ, and amyloid pathology in the 
pathogenesis of AD. Although APP transgenic mice exhibit many of the key features 
of AD, neurofibrillary tangles are notably absent (Chin 2011).  
 
Table 3.1 gives an overall summary of few widely used animal models in AD.  
However the following points should be kept in mind before choosing an animal 
model (Chin 2011). 
1. None of the currently available transgenic lines fully recapitulate all aspects of AD, 
although several lines are able to recreate one or more of the major pathological 
hallmarks. 
2. Different lines of transgenic mice exhibit varying ages of onset of impairment. This 
is an important consideration both for scientific and practical reasons. The animal 
model needs to be chosen according to the scientific questions. Early age of onset and 
fast disease progression may be useful for biochemical investigations but if behavioral 
training and therapeutics is involved, late onset and slow disease progressing line 
should be chosen (Chin 2011).  
3. The background strains on which transgenic mice have been created are important 
to consider, particularly for behavioral analysis. Inbred mice often show less 
variability than outbred mice. Outbred mice have been used in many studies that have 
advanced our understanding of AD, but it is important to keep in mind that larger 
sample size may be required (Chin 2011).  
4. Different inbred strains have different behavioral profiles, and some strains are 
‘better learners’ than others or are more active than others etc (Chin 2011).  
 
Finally, this repository of transgenic mice offers a wealth of opportunity to investigate 
the cellular mechanisms underlying AD, and the choice of mouse model for research 
should be guided by the specific questions to be answered. 
 
In this dissertation, we used APPswe mice, which has slow growing AD pathology 
with initial plaques appearing around age of 8-10 months (Hsiao, et al. 1996). 
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3.1.6 Therapeutic strategies 
Despite decades of research, till today there is no cure for AD. The available 
treatments offer relatively small symptomatic benefit and largely remain palliative in 
nature. At the moment, there are only four FDA approved drugs in the market. Three 
of them (Donepezil, Galantamine and Rivastigmine) are acetylcholinesterase 
inhibitors and thus increase the cholinergic transmission in the brain. These drugs are 
used in mild to moderate disease. The fourth drug, Memantine, is a noncompetitive 
NMDA receptor antagonist and helps to reduce the neurotoxicity.  Memantine is 
approved for treating the advanced stages of AD. Various new drug targets have been 
identified over the last decades. The categories include immunotherapy (Schenk, et al. 
1999), Aβ aggregation inhibitors (Roberson and Mucke 2006), β and γ secretase 
inhibitors (Chang, et al. 2007, Roggo 2002, Siemers, et al. 2006), neurotropins  
(Tuszynski, et al. 2005), antioxidants (Jama, et al. 1996), statins (Fassbender, et al. 
2001, Jick, et al. 2000), NSAIDs (Aisen, et al. 2003, Hirohata, et al. 2005, in t' Veld, 
et al. 2001), PPARγ agonists (Roberson and Mucke 2006) calcium channel blockers 
(Roberson and Mucke 2006), glycogen synthase kinase inhibitors (Roberson and 
Mucke 2006), phosphodiesterase inhibitors (Roberson and Mucke 2006), hormone 
replacement therapies (Casadesus, et al. 2007, Webber, et al. 2005) and 
Mediterranean diet (Scarmeas, et al. 2006) to name a few. Huge clinical trials are 
currently under way to prove the efficacy of these drugs.  
 
Of all the new strategies mentioned above, immunotherapy has been the most 
promising with hundreds of reports over the last decade. In 1999, Schenk et al. 
reported the first evidence that active Aβ immunotherapy could reduce Aβ pathology 
in vivo.  Ever since then, the AD community has been trying to validate the 
immunotherapy approach (DeMattos, et al. 2001, Hock, et al. 2003, Janus, et al. 2000, 
Morgan, et al. 2000, Spires-Jones, et al. 2009, Wilcock, et al. 2004a, Wilcock, et al. 
2004b). Both active (injecting Aβ peptide) and passive (injecting anti-Aβ antibody) 
have been applied in various mice models and some of these have been tried in 
humans too. To mention one human trial, in 2000, a randomized placebo-controlled 
Phase IIa trial with vaccine AN1792 (synthetic form of Aβ 1-42 and surface-active 
saponin adjuvant QS-21) was initiated. However, the trial was stopped in 2002 after 
6% of patients developed aseptic meningioencephalitis and leukoencephalopathy  
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(Bayer, et al. 2005, Gilman, et al. 2005). Even though this trial raised several 
questions about the safety of the vaccine, a cohort of the antibody responder patients 
did show cognitive improvement, reduced plaque load, increase in brain volume and 
serum titers of anti-Aβ antibodies (Fox, et al. 2005, Hock, et al. 2002, Nicoll, et al. 
2003, St George-Hyslop and Morris 2008). 
 
Several mechanisms could explain how antibodies directed at amyloid-β (Aβ) 
promote the clearance of this peptide in vivo (Lemere and Masliah 2010). When anti-
Aβ antibodies form complexes with Aβ peptides, the Fc portion of the antibodies 
might bind the Fc receptor on microglia, inducing phagocytosis of these complexes 
(Bard, et al. 2000). This mechanism would require that anti-Aβ antibodies cross the 
blood–brain barrier (BBB) and bind Aβ within the CNS. Some evidence has been 
reported to support this mechanism; however, two studies have demonstrated that Fc 
mediated phagocytosis is not required for immunotherapy-induced Aβ clearance  
(Bacskai, et al. 2002, Das, et al. 2003). In an alternative mechanism, anti-Aβ 
antibodies in the blood might cause a shift in the concentration gradient of Aβ across 
the BBB, thus resulting in an increase in Aβ efflux from the brain to the periphery 
(DeMattos, et al. 2001, Lemere, et al. 2003). Aβ antibodies might bind and remove 
small Aβ aggregates, thereby neutralizing the effects of toxic Aβ species on synapses 
(Klyubin, et al. 2005). One study suggests that certain antibodies (for example, a 
midregion Aβ antibody, m266) sequester monomeric Aβ inside the brain, facilitating 
clearance of the peptide and preventing build up of toxic, aggregated forms of Aβ 
(Yamada, et al. 2009). Several of these proposed mechanisms are depicted in Figure 
3.7. 
 
These proposed mechanisms of Aβ clearance by immunotherapy are not mutually 
exclusive and might be disease stage-dependent. For example, a preventive vaccine 
administered before cerebral amyloid accumulation might not require that the 
antibodies cross the BBB to enhance Aβ clearance and maintain Aβ in its monomeric 
state. By contrast, a therapeutic vaccine (delivered once plaque deposition is well 
underway) would probably benefit from the transport of Aβ antibodies into the CNS 
to induce Aβ phagocytosis and neutralize local Aβ toxicity. Circulating anti-Aβ 
antibodies in the periphery might pull Aβ from brain to blood for clearance, thereby 
preventing further deposition (Lemere and Masliah 2010).  More in vivo studies 
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looking at the plaque-antibody interactions are required dissect out the mechanism of 
action. 
 
        
 	   Figure 3.7: Proposed mechanism of action of immunotherapy. Image adapted from Brody and 
Holtzman 2008. 
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3.1.7 Microglia in AD 
Microglia are brain-resident macrophages derived from myeloid cells in the periphery 
and comprise approximately 12% of cells in the brain (Block, et al. 2007). In the 
mature brain, microglia typically exist in a resting state characterized by ramified 
morphology and highly dynamic monitoring of the brain environment (Davalos, et al. 
2005, Nimmerjahn, et al. 2005). Microglial overactivation is an early pathogenic 
event that precedes neuropil destruction in patients with AD (Cagnin, et al. 2001). 
Even before the development of symptoms, activated microglia cluster at the sites of 
aggregated Aβ and penetrate neuritic plaques (McGeer, et al. 1987, Veerhuis, et al. 
1999).  
 
Soluble and insoluble fibrillar Aβ can bind to a plethora of receptors expressed by 
microglia (Figure 3.8). At least in vitro, microglia are able to take up Aβ after direct 
or indirect binding to its respective receptors (Rogers and Lue 2001, Rogers, et al. 
2002). Traditionally, focus of intensive research was the inflammatory and oxidative 
response of microglia stimulated by fibrillar Aβ. Upon stimulation with fibrillar Aβ, 
microglia can respond by secretion of neurotoxic and neuroprotective molecules. 
Among the most prominent factors considered to be neurotoxic in AD are cytokines 
(e.g., TNFα, IL-1, IL-6), chemokines, complement factors, prostanoids, and reactive 
oxygen species like superoxide and nitric oxide (Akiyama, et al. 2000). But microglia 
can also produce ‘beneficial’ cytokines such as IL-4, IL-10 and transforming growth 
factor – β (TGFβ), which may reduce neuroinflammation and thereby modulate 
disease progression (Tesseur, et al. 2006, Wyss-Coray 2006). One of such receptor, 
which controls microglial neurotoxicity, is fractalkine receptor (CX3CR1) (Cardona, 
et al. 2006). Knocking out of this receptor prevents neuronal loss indicating the 
critical role of CX3CR1 receptor in neuron-microglia communication (Fuhrmann, et 
al.).  In CRND8 AD mouse model, deletion of CX3CR1 resulted in lower brain levels 
of Aβ 1-40 and Aβ 1-42 and CX3CR1 deficient microglia had greater phagocytic 
ability thus leading to greater amyloid content within microglial phagolysosomes 
(Liu, et al. 2010). Another study reported that ablation of microglia using thymidine 
kinase of herpes simplex virus in APP/PS1 mouse model did not alter either amyloid 
plaque formation, maintainence or amyloid associated neuritic dystrophy (Grathwohl, 
et al. 2009). Moreover, it is known that systemic application of anti-Aβ antibody 
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results in increased in both number of microglia and number of cellular processes per 
cell within 72 hours of application (Koenigsknecht-Talboo, et al. 2008). Thus, exact 
role of microglia in development of AD pathology and it’s response after therapeutic 
treatments still need to be explored in greater detail.  
 
                           
 
The interplay between amyloid plaques and microglia is highly dynamic Bolmont, et 
al. 2008, showed in a transgenic AD mouse model, that the number of plaque 
associated microglia increased over time either via proliferation or infiltration. 
Microglial cells quickly migrated towards newly developed plaques and extend their 
processes towards the plaques. Microglia at the interface of the plaque were highly 
dynamic and showed membrane movement and process motility. Larger plaques were 
surrounded by larger microglia. The size of plaques corresponded over time to the 
volumes of the surrounding microglial cells. Interestingly, it seemed that there was a 
relationship between microglial cell volume and number; increase in the cell volume 
of microglia was accompanied with fewer cells in the vicinity of a plaque. It was 
Figure 3.8: Plaque-microglia dynamics: Soluble Aβ (-), generated by neurons (Neu) is toxic to 
neurites and synapses. Soluble Aβ also seems to be sequestered from amyloid plaques. “Resting 
microglia” (Mi) become recruited to the amyloid plaques. Two populations could account for the 
increase in microglia: First, endogenous brain microglia migrate to the lesion and proliferate. 
Second, peripheral blood cells, e.g. Ly- 6ChiCCR2+monocytes (Mo), are recruited from the 
periphery and cross the blood-brain-barrier. Aβ can bind to a plethora of microglial receptors. 
Microglia become activated (A-Mi) and secrete neurotoxic and/or anti-inflammatory molecules. In 
addition, some microglia may have the ability to take up soluble or insoluble forms of Aβ. SR: 
Scavenger Receptor; TLR-Toll-like-receptor; CR-Complement receptor; MHC-II: major 
histocompatibility class II; BBB: blood brain barrier. Image adapted from Schlachetzki 2009.  
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hypothesized to be a compensatory mechanism. A limited number of microglia in the 
vicinity of a plaque could respond with larger cell bodies to cover the plaque. The 
plaque size changed over time; the smaller plaques got bigger and the bigger plaques 
smaller (Bolmont, et al. 2008). The growing plaques had an initial smaller size with 
only little microglial coverage. The plaques that decreased in size over time had the 
highest number of microglial cells. This could imply that a sufficient number of 
microglia can prevent plaque growth by preventing the transformation of local soluble 
Aβ to insoluble fibrillar Aβ and by an uptake of the sequestered soluble Aβ. 
Furthermore, it points towards the potential of microglia to phagocytose and/or 
degrade Aβ extracellularly. Still, only scarce information is available about the role of 
microglia before, during and after plaque deposition occurs and how it modulates 
neuronal activity. There are few two-photon imaging studies that have addressed the 
question of microglia and neuronal interaction. Fuhrman el al showed that knocking 
out of CX3CR1 receptor prevents neuronal loss indicating the critical role of 
CX3CR1 receptor in neuron-microglia communication.  We tried time-lapse imaging 
of GFP expressing microglia AD transgenic before and after topical antibody 
application as a means to understand plaque-microglia interactions. 
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3.2 In Vivo Two-photon Imaging in Neocortex 	  
Scientists have always fancied visualization of live cells. Imaging with high 
resolution in the living animal while extracting quantitative information has become a 
reality now (Kerr and Denk 2008). The in vivo imaging spectra encompasses various 
modalities ranging from magnetic resonance imaging (MRI), functional MRI (fMRI), 
computed tomography (CT), positron emission tomography (PET) to optical imaging 
techniques such as optical coherence tomography and nonlinear optical imaging (two-
photon microscopy). MRI, fMRI, CT and PET allow the imaging of the whole brain 
and offer very good temporal resolution, however, their spatial resolution of few 
millimeters is a limiting factor. Of all the currently available in vivo imaging 
techniques, two-photon laser scanning microscopy (2PM) is able to study both the 
structure and function of nervous system at high spatial resolution, resolving 
individual cells, which has been the main focus of this dissertation work.   
 
3.2.1 In vivo two-photon microscopy 
2PM emerged as a technique in 1990 (Denk, et al. 1990), although two-photon 
excitation has been predicted around 1930 (Göppert-Mayer 1931). In 2PM, 
fluorescent molecules are excited by the quasi-simultaneous absorption of two near-
infrared photons (Figure 3.9A). Two-photon excitation has a quadratic dependence on 
excitation intensity and therefore produces excitation only in a small focal volume; 
negligible out-of-focus fluorescence is generated, causing intrinsic optical sectioning, 
reduced background and reduced photobleaching and photodamage outside the plane 
of focus. In practical terms, 2PM makes it possible to acquire high contrast images by 
using a wavelength that is less harmful to live cells. In particular the use of near-
infrared light makes it possible to image deeper in the tissue, owing to less scatter of 
the incident light and the localized excitation makes 2PM less sensitive to light 
scattering because all photons can be correctly assigned to focal volume. Due to these 
special features, 2PM has become the method of choice for high-resolution, deep 
tissue, intravital microscopy  (Helmchen and Denk 2005). 
 
To improve the efficiency of two-photon excitation, ultrafast lasers emitting short 
pulses (<100 fs) of light at a rapid frequency (∼100 MHz) are used. Using these 
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lasers, very large peak intensity can be achieved in a repeated pulse train to sustain 
fluorophore excitation exclusively at the focal plane where the density of the photon 
flux is sufficiently high. Typically, Titanium:Sapphire (Ti:Sapphire) lasers with 
average power of  >1W and tunable wavelength in the range of 670-1,070 nm are 
used (Figure 3.9B).  
 
 
                    
 
 
A simple and efficient detection pathway is used in 2PM to capture as many of the 
potentially highly scattered signal photons as possible. In most systems a ‘whole-area’ 
epifluorescence detection scheme is used, with all the light that is collected by the 
objective also guided onto the detector (Figure 3.9B) (Helmchen and Denk 2005). For 
small or transparent specimens trans-fluorescence collection is used. However, in 
deep scattering specimens epicollection is the only practical mode that can be used  
(Helmchen and Denk 2005).  	  
 
Figure 3.9: Principle of two-photon microscopy (A) Simplified Jablonski diagram showing two-
photon excitation process. (B) Schematic of a two-photon microscope with epifluorescence and 
transfluorescene detection as used in this dissertation. Images adapted from Helmchen and Denk 
2005.  
Introduction 	  
	  	   37	  
 
Ever since its discovery, 2PM has opened up new avenues in high-resolution imaging 
of intact tissues and living animals and is still an expanding field. Systems as diverse 
as immune system (Bousso and Robey 2004), renal system (Molitoris and Sandoval 
2005), cardiovascular system (Rubart 2004), respiratory system (Nava, et al. 2010), 
skin (Laiho, et al. 2005) and nervous system (Helmchen and Denk 2002) have been 
examined in detail at depths of up to few hundred microns using 2PM, while leaving 
the tissue intact (Helmchen and Denk 2005). Observing the same cells over time is 
often more sensitive and more physiologic than trying to deduce how cells change 
from ‘snapshots’ of fixed tissue (Misgeld and Kerschensteiner 2006). Observation of 
the sequence of pathological events can establish their causative relationship and the 
pathology can be compared before and after therapeutic intervention. Nervous system 
is a highly dynamic organization of neurons and glial cells, where information 
exchange occurs in time scale of milliseconds. Thus, making it an optimum system 
for 2PM, which has been utilized to study neuronal activity (Busche, et al. 2008, 
Grienberger, et al. 2012), microglial dynamics (Nimmerjahn, et al. 2005) and 
astrocyte activity (Kuchibhotla, et al. 2009). Furthermore, 2PM is also a useful tool to 
study disease progression and has been used to study pathophysiology of different 
disease models (discussed in detail below).  We have applied the principles of long 
term imaging for structural and functional imaging of nervous system in our project.  
 
With the development of new in vivo fluorescence techniques, 2PM is currently 
widely used in all fields of neurobiology.  With the development of various types of 
genetically modified mice and vital dyes, it is now possible to image almost all the 
cell types in the mammalian brain, such as dendrites, axons (Lee, et al. 2006, Portera-
Cailliau, et al. 2005), microglial (Jung, et al. 2000), astrocytes (Nimmerjahn, et al. 
2004) and oligodendrocytes (Fuss, et al. 2000, Nolte, et al. 2001). Congo red derived 
dyes such as Methoxy-X04 can be injected intraperitoneally and stain the beta-
amlyoid plaques specifically (Klunk, et al. 2002). Viral labeling strategies also 
available and can be combined with transgenic mouse lines (Dittgen, et al. 2004).  
Intravenous injection of high molecular weight dextran allows labeling of 
neurovascular structures too (Bacskai, et al. 2002). Even cellular compartments can 
be labeled in vivo with fluorescent proteins by attaching them to membrane proteins 
or by using specific targeting sequences (De Giorgi, et al. 1999). Thus, almost all 
Introduction 	  
	   38	  
cellular subtypes can be tagged, labeled and imaged. We have been able to label and 
image neurons, microglia, astrocytes, blood vessels and beta-amyloid plaques in this 
project.  
 
As exciting as the field of two-photon microscopy is, it is important to understand the 
limitations of the technique. High-resolution optical imaging techniques are currently 
practically limited to within 500 µm (with most optimum preparations may be 800 
µm) of the brain tissue. As a consequence, in the brain, these techniques are more 
suitable for the examination of grey matter diseases than white matter diseases, and 
favor studying pathology in the cortex (for example, Alzheimer’s disease) over 
changes in deeper brain regions (for example, Parkinson’s disease) (Misgeld and 
Kerschensteiner 2006). However, the anatomy is reversed in the spinal cord, where 
the axon tracts lie superficially and white matter pathology (such as axon trauma) is 
easier to study than grey matter pathology (such as motor neuron degeneration). Few 
other points have to be kept in mind, it is crucial that robust labeling exists for the 
cells that mediate a given disease and disease models with a well-defined trigger and 
time course are best suited for in vivo studies (Misgeld and Kerschensteiner 2006).  
 
In vivo imaging has been used to study various nervous system dysfunction models--- 
neurodegenerative diseases such as Alzheimer’s disease (Bacskai, et al. 2002, Busche, 
et al. 2008), amyotrophic lateral sclerosis (ALS) (Schaefer, et al. 2005); spinal cord 
injury and trauma models (Kerschensteiner, et al. 2005); ischemia and stroke models 
(Zhang, et al. 2005a, Zhang, et al. 2005b); neuroinflammation models such as 
experimental autoimmune encephalomyelitis (EAE) (Kawakami, et al. 2005, Nitsch, 
et al. 2004). Below we will summarize the 2PM studies in field of AD (see 3.4).  
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3.2.2 Calcium indicators to study neuronal networks 	  
Two-photon calcium imaging is currently the prevailing optical method for probing 
neuronal networks in vivo (Garaschuk, et al. 2006). The rational is that rises in 
cytosolic calcium can be used as an indirect measure of neuronal activity. When 
neurons fire action potentials, voltage gated calcium channels in the plasma 
membrane open up and lead to a rise in cytosolic calcium within few milliseconds  
(Garaschuk, et al. 2006). Detecting these changes with a fluorescent calcium indicator 
has been used to monitor activity of large numbers of neurons optically within the 
brain of living animals (Garaschuk, et al. 2006, Gobel and Helmchen 2007).  The 
family of calcium indicators can be broadly divided into synthetic calcium 
indicators and genetically encoded calcium indicators.  
 
The field of synthetic calcium indicators was revolutionized with the discovery of 
BAPTA and in particular Oregon Green BAPTA-1 (OGB), a fluorescent 
polycarboxylate compound with strongly improved fluorescence properties (Tsien 
1981, Tsien 1989). The acetoxymethyl esters (AM esters) of these compounds can be 
noninvasively loaded into living cells (Tsien 1989, Tsien 1992). Because of their 
properties such as high sensitivity for calcium, fast binding and dissociation kinetics, 
fairly linear response properties, pH-resistance and photostability, over the last two 
decades AM dyes have been extensively used to study activity of neuronal 
populations. Unfortunately, there are several drawbacks of using synthetic calcium 
dyes in intact brain tissue. To name a few; compartmentalization of the dye to cellular 
organelles or leaking out of cells during long recording periods, diffuse and 
indiscriminate labeling of neuronal architecture, short duration (4-6 hours) of staining 
after loading and chronic imaging is impractical (Mank and Griesbeck 2008).  
 
A breakthrough in the area of in vivo calcium imaging was achieved in 1997 with the 
development of genetically encoded calcium indicators (GECIs) based on green 
fluorescent protein (Miyawaki, et al. 1997). The term ‘genetically encoded’ refers to 
the fact that the sensors are solely composed of amino acids with no addition of any 
synthetic compound or cofactor that would be difficult to apply into a living brain. 
Thus, these sensors are encoded by a stretch of DNA that can be manipulated, 
mutated by recombinant DNA technology. When the DNA coding for the sensor is 
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delivered into a cell, the sensor is formed within the cell in situ. Combined with the 
use of cell-type specific promoters, cellular targeting sequences and transgenic 
technology, GECIs offer a noninvasive means to implant an indicator deeply within a 
living tissue (Mank and Griesbeck 2008).  
 
During the last decade, several classes of fluorescent protein calcium sensors utilizing 
different mechanisms of activation have been designed (Figure 3.10). Most of these 
use calmodulin as the transducer protein and only recently calcium sensors using 
other calcium-sensitive proteins have been explored (Heim and Griesbeck 2004, 
Mank, et al. 2006). It was subsequently observed that some of the calmodulin-based 
sensors undergo specific interactions with other proteins in the neuronal cytoplasm, 
which render the sensor partially calcium insensitive (Hasan, et al. 2004, Palmer, et 
al. 2004). Thus, a new generation of probes with mutations in calmodulin interaction 
sites were designed, which has led to further improvements of performance (Heim 
and Griesbeck 2004, Palmer, et al. 2004).  FRET-based sensors employing troponin C 
as calcium binding moiety are also promising (Mank, et al. 2008). 
 
                          
Figure 3.10: Genetically encoded calcium indicators. Four well explored designs (a) Yellow 
cameleon, (b) Camgaroo, (c) G-CaMP/Pericam, (d) TN-L15. Fluorescent reporter proteins are cyan 
(CFP), yellow (YFP) and green (GFP) fluorescent proteins. Calmodulin, the calmodulin binding 
polypeptide M13 (M13) or troponin C are sandwiched between a CFP-YFP FRET pair (a,d), inserted in 
YFP (b) or attached to a circularly  permuted fluorescent protein (cpFP). Also shown is the 3x 
magnified molecular structure of the non-protein calcium indicator, Fura-2, for comparison. Image 
adapted from Knopfel 2006. 
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The first generation of ‘yellow cameleons’ (YC) were called so because of their color 
change from bluish to yellowish on excitation and extension of M13 into and out of 
the mouth of calmodulin like a large tongue (Miyawaki, et al. 1997). YC3.60 (Figure 
3.11), the indicator that was used in this dissertation work was generated using 
circular permuted Venus 173 variant (cpVenus173) as a YFP FRET partner of CFP 
and showed efficient FRET responses with a large dynamic range in cuvette and 
cultured HeLa cells (Nagai, et al. 2004). However, functional characterization of 
YC3.60 had remained incomplete until now. It was recently shown that YC3.60 under 
human synapsin promoter (delivered using AAV2 vector) reported both spontaneous 
and whisker evoked neuronal activity with high sensitivity and dynamic range 
(Lutcke, et al. 2010). Calcium measurements were performed from individual apical 
dendrites of cortical neurons as well as from population of neurons using two-photon 
microscopy. It was also demonstrated that YC3.60 calcium signals in rodent barrel 
cortex could be read out in a bulk fashion (Lutcke, et al. 2010). With the development 
of gene delivery with the use of recombinant viral vectors using lentivirus and adeno-
associated virus (Dittgen, et al. 2004, Wallace, et al. 2008), it is now possible to study 
neuronal ensembles in vivo over a period of weeks to months (Tian, et al. 2009).   
 
              
Figure 3.11: YC3.60. (A) Structure of YC3.60 (B) construct of the indicator (highlighted in blue), 
(C) excitation emission spectrum of YC3.60 (highlighted in blue), (D) response property for 
physiologic calcium concentration (blue arrow). Images adapted from Kotlikoff 2007, Nagai et al. 
2004.  
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Other indicators apart from YC3.60 which have been used are Camgaroo 1 and 2 in 
Drosophila model (Yu, et al. 2003), inverse pericam in zebrafish and mouse olfactory 
bulb (Li, et al. 2005, Yu, et al. 2003), D3cpV in mouse cortex (Wallace, et al. 2008), 
TN-XL in Drosophila (Mank, et al. 2008), GCaMP2 in mouse olfactory bulb and 
mouse cerebellum (Diez-Garcia, et al. 2005, Fletcher, et al. 2009), GCaMP3 in mouse 
cortex, mouse hippocampus, Drosophila and C. elegans (Dombeck, et al. 2010, 
Seelig, et al. 2010, Tian, et al. 2009). All these studies imaged neuronal network 
ranging from few days to months. However, there are many disadvantages of GECIs 
as well; such as poor signal-to-noise ratio, low sensitivity for detecting calcium 
transients and inability to resolve single action potentials (Liebscher and Meyer-
Luehmann 2012). It has also been reported that some of the indicator can cause cell 
damage (Tian, et al. 2009). Technical developments such as more sensitive cameras, 
new lasers, improved software, commercial imaging setups are making chronic 
imaging more realistic (Looger and Griesbeck 2012). Thus, GECIs even though offer 
great opportunity to study long term functional imaging, is still work under progress.  
 
3.2.3 Rodent barrel cortex 	  
We needed a model system in order to study the effects on neuronal excitability. We 
chose barrel cortex as the model system because it is a very well developed 
somatosensory region in rodents. Rodents, being nocturnal animals, must gather 
information about their surroundings without use of vision. It is this reason that 
evolution has gifted them with highly sensitive array of facial whiskers (Figure 
3.12A). With the use of whiskers, rodents can build spatial representation of their 
environment, locate objects and perform texture discrimination (Petersen 2007). The 
whiskers are arranged in a highly organized pattern allowing identification of 
individual whiskers (Figure 3.12B).  
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The sensory information from the whiskers is processed in the primary somatosensory 
cortex (S1) or the so-called ‘barrel cortex’, where each whisker is represented by a 
discrete and well-defined structure in layer 4 (Woolsey and Van der Loos 1970). 
These layer 4 ‘barrels’ are somatotopically arranged in an almost identical fashion to 
the layout of the whiskers on the snout and the barrels can be easily visualized both in 
living and stained brain slices (Finnerty, et al. 1999, Petersen and Sakmann 2000). 
This barrel map, by and large is genetically specified and forms early in development. 
Deflection of a whisker probably opens mechanogated ion channels in nerve endings 
of sensory neurons innervating the hair follicle. The resulting depolarization evokes 
action potential firing in the sensory neurons of the trigeminal nerve, which are 
relayed in the ventral posterior medial (VPM) nucleus of thalamus and finally 
projected to the primary somatosensory cortex (Petersen 2007).	  	  A stimulus delivered 
to a layer 4 barrel first causes depolarization within layer 4 barrel, which then in the 
subsequent milliseconds spreads to depolarize neurons in layer 2/3 in a strictly 
columnar fashion. 2PM has been able to record single action potentials from evoked 
calcium transients in layer 2/3 neurons as response to whisker stimulation (Kerr, et al. 
2007). It’s also known that probability of neuronal response is higher in the barrel 
than above the septa or neighboring barrel (Kerr, et al. 2007). Thus, the barrel cortex 
sensory system is an attractive model for investigating active sensory processing and 
sensorimotor integration.  
 
Figure 3.12: Rodent whiskers. (A) Organized array of whiskers (B) Pattern and naming of 
whiskers. The rows are named A-E top to bottom and the arcs 1,2,3… antero-posteriorly (C) 
direction of movement of whiskers. Images adapted from Petersen 2003.  
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The well-defined somatotopic map of whiskers allows the use of optical techniques to 
map the whiskers. In the mouse, highly localized intrinsic signals can be evoked by 
repetitive deflection of a particular whisker can be imaged through the intact skull 
(Orbach, et al. 1985). The physical basis of the intrinsic signals are related to changes 
in blood flow and are therefore similar to those underlying in the blood oxygenation 
level-dependent (BOLD) signal observed in fMRI. Intrinsic optical imaging has the 
advantage of being quick and extremely reliable (Petersen 2007).  
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3.4 Two-Photon Microscopy in AD research 	  
Application of 2PM in AD research is a relatively new approach and the first 
promising reports are just a decade old. The very first study, which used the technique 
of 2PM in AD, was Christie, et al 2001. They were able to image beta-amyloid 
plaques in Tg2576 mice using thioflavine-S and did not see any change in plaque 
growth over a period of 5 months (Christie, et al. 2001). Since then, the focus has 
been on in vivo imaging of beta-amyloid plaques and the surrounding cellular 
changes. Structural imaging of neurites in the vicinity of beta-amyloid plaques has 
shown pathology such as synapse loss (Spires, et al. 2005, Tsai, et al. 2004), neuritic 
dystrophy and breakage (Spires, et al. 2005, Tsai, et al. 2004).  Some models such as 
APP/PS1 showed ongoing enhanced spine formation and elimination within the pre-
plaque region (Tsai, et al. 2004), where as other models such as older Tg2576 mice 
showed increased spine elimination and decreased formation (Spires-Jones, et al. 
2007).  Even the triple transgenic mouse model of AD showed apparent hippocampal 
and frontal cortex spine loss only after plaque deposition (Bittner, et al. 2010). Some 
studies also observed increase in structural plasticity (Spires-Jones, et al. 2009) and 
rapid recovery of amyloid-associated neuritic dystrophy (Brendza, et al. 2005).  
 
Numerous studies have reported direct observation of plaque clearance after direct 
application of anti-Aß antibody on the brain surface (Bacskai, et al. 2001, Prada, et al. 
2007). Apart from plaque clearance, 2PM was also used to address the question of 
growth of plaques over time, a controversial field in itself. A landmark study reported 
that beta-amyloid plaques appear rapidly in the time frame of 24 hours, and did not 
change further after appearance (Meyer-Luehmann, et al. 2008). However, recently 
two more groups reported steady increase in all plaques either independent of plaque 
size (Hefendehl, et al. 2011) or higher growth rate for newly deposited plaques 
(Burgold, et al. 2011). 2PM has also been used to study CAA. Longitudinal imaging 
of AD transgenic mice showed that CAA is a multifactorial event in the form of band-
like Aß deposits (Robbins, et al. 2006). It was also shown that passive immunization 
is able to halt CAA progression and even reduce vascular amyloid in AD transgenic 
mice (Schroeter, et al. 2008).  
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Although, much of the research has been plaque and immunotherapy centric, other 
aspects of the disease are also being addressed. Chronic imaging of microglia 
revealed the crucial role of microglia in plaque maintenance (Bolmont, et al. 2008). 
Astrocytes too showed synchronous hyperactivity and intercellular calcium waves 
(Kuchibhotla, et al. 2009). Aberration in calcium homeostasis causing structural and 
functional disruption of neuronal networks was seen (Kuchibhotla, et al. 2008). Thus, 
study of calcium imaging can be employed to understand neuronal activity. Busche, at 
al. reported cluster of hyperactive neurons near amyloid plaques (with in 60 µm from 
plaque) in APP/PS1 transgenic mice and decreased number of ‘silent’ neurons 
compared to wild type control mice. More recently Grienberger et al. studied 
spontaneous and visual-evoked response in visual cortex of APP/PS1 mice and 
reported progressive deterioration of neuronal tuning for orientation of visual stimuli, 
which occurred in parallel with age-dependent increase of beta-amyloid load. 
Furthermore, they also showed that this deterioration was seen only in neurons that 
were hyperactive during spontaneous activity (Grienberger, et al. 2012).  It is worth 
noting that, Busche, et al. and Grienberger, et al. used synthetic calcium indicator 
OGB-1 for calcium imaging, which are limited to acute experiments and although 
were recently used for longitudinal imaging by Busche, et al., they have several short 
comings. The answer lies in the use of genetically encoded calcium indicators. Only 
chronic imaging can provide us the answers to long-term modulation of neuronal 
activity. In this dissertation work we performed longitudinal study of neuronal 
network in an in vivo setting, which so far hasn’t been done and will help in 
understanding modulation of neuronal activity in Alzheimer’s disease animal models.  
 
The field is fairly young and there are many unresolved questions such as how is the 
spontaneous activity altered in transgenic mice? how does the neuronal network 
respond to a sensory stimulation? how does the spatial functional organization of 
cortical representation change in terms of network activation patterns? how do 
correlations among neurons within neuronal ensemble changes? what are the effects 
of systemic application of anti-Abeta immunotherapy on a neuronal network?  how is 
the neuronal activity altered on such an event? etc. One of the challenges is to 
establish paradigms, which will allow imaging of same animal over time, allowing the 
study of pre-plaque phase of AD pathology and its alteration upon therapeutic 
intervention. There have been no longitudinal studies measuring neuronal activity in 
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AD mice models. Even though genetically encoded calcium indicators have been used 
(Kuchibhotla, et al. 2008), their application to study neuronal activity have not been 
completely explored. Also, there have been no studies to measure stimulus-evoked 
activity at network level. This motivated us to study sensory-evoked activity of barrel 
cortex neurons chronically, using whisker stimulation as a sensory stimulus in AD 
mice models with the help of genetically encoded calcium indicators. 
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3.5 Aim and outline of thesis  	  
The main goal of this thesis work was to apply the techniques of two-photon 
microscopy and genetically encoded calcium indicators for analysis of neuronal 
response in transgenic mouse models of brain amyloidosis, There were two main 
aspects: morphological and functional. The morphological aspect was to image the 
microglia before and after immunotherapy and the functional aspect was to study 
neuronal networks with and without sensory stimulus.  
 
Questions we tried to address the following questions: 
1. How is the spontaneous activity altered in pre-plaque pathology in animal 
models of brain amyloidosis? How does the neuronal network respond to a 
sensory stimulation in these mice compare to wild type mice?  
2. What are the effects of systemic application of anti-Abeta immunotherapy on 
a neuronal network?   
3. How is the neuronal activity altered on such an event?  
 
The specific goals were as follows: 
1. To establish chronic in vivo imaging paradigm in living transgenic mice 
2. To image amyloid plaques, microglia, astrocytes, neurons and blood vessels 
             in the brains of living transgenic mice 
3. To establish repeated functional imaging from the same neurons over 
extended periods of time using genetically encoded calcium indicators 
4. To investigate spontaneous and whisker-evoked activity for measuring 
neuronal responses in pre-plaque phase of transgenic mouse model of brain 
amyloidosis 
5. To explore the possibility of the 2PM for evaluating immunotherapy 
approaches  
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The first step in the project is to establish chronic imaging protocols which includes 
development of head posts to provide stability during long imaging session and 
explore novel techniques of cranial window preparations which are optically 
conducive for longitudinal imaging. The paradigms are standardized by using 
APPDE9;CX3CR1 heterozygous mice which expressed GFP-positive microglia. 
These protocols are further tested by applying anti-Aβ antibody topically or by bulk-
loading in the vicinity of plaque and performing time-lapse imaging in these mice. 
The next step then is to inject genetically encoded calcium indicators in barrel cortex 
of young transgenic mice models of brain amyloidosis, which are in pre-plaque stage.  
Later, chronic windows are implanted and intrinsic imaging performed to map 
whisker in the area of viral expression. Although these mice are in pre-plaque stage, 
Methoxy-X04 is injected prior to each session to observe development of plaques in 
the imaging area.  Baseline imaging sessions are performed and subset of mice 
receive systemic anti-Aβ antibody. Spontaneous activity and evoked response of same 
cells over time was measured and comparisons of wild type control, antibody treated 
and vehicle treated transgenic mice. We further analyze the data for amplitude of 
Transgenic mouse model 
of brain amyloidosis
Chronic Imaging
Immunotherapy
and Microglia
Neuronal Dysfunction
Figure 3.13: Goals of thesis. To use the technique of chronic imaging to image beta-
amyloid plaques and other cellular structures in brain of AD mouse models. Images 
are from internet.  
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response, response probability between different groups wt control, antibody treated 
and vehicle treated was also measured. The project overall is technically challenging 
as most of the protocols had to be standardized.  
 
Chapter 5.1 discusses the standardization of various technical aspects, which were 
required for chronic imaging. Chapter 5.2 is an ensemble of different techniques, 
which were used to study plaque-microglia interactions. Chapter 5.3 discusses the use 
of genetically encoded calcium indicators to study neocortical neuronal network 
activity in transgenic AD models.  
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4.1 Animals 
All experimental procedures were performed as per the guidelines of University of 
Zurich and Swiss veterinary cantonal office (BVET), under the licenses 155/2007 and 
210/2010.  The transgenic lines used were: APP/PS1dE9, APPsweArc (ArcAbeta), 
APPswe and CX3CR1. The APPswe, APP/PS1dE9 and CX3CR1 lines were obtained 
from The Jackson Laboratory. The APPsweArc were generated in house and 
previously described (Knobloch, et al. 2007b). Both lines were under prion promoter. 
The APP/PS1dE9 and APPsweArc mice were crossed with CX3CR1 -/- mice to 
generate APP/PS1dE9;CX3CR1 +/- and APPsweArc;CX3CR1 +/- mice. The 
genotype of mice was determined by PCR of tail biopsy DNA (Supplementary 1). 
Non-transgenic littermates were used as controls when specified. All animals were 
housed in the groups of 2-6 per cage in Type 3 or Type 2 long cages. After the 
implantation of the chronic cranial window, mice were individually housed. The 
animals were kept under 12-hour light/dark cycle and had ad libitum access to food 
and water.    
  
4.2 Surgical Procedures 
4.2.1 Anesthesia 
Isoflurane was used for induction of anesthesia as well as for longer duration 
anesthesia of maximally 4 hours for most surgeries and experiments. For anesthesia 
induction, animals were kept inside a chamber with 5% isoflurane (Baxter, 
Volketswil, Switzerland) and oxygen (800-1000 ml/min) until anesthetized. A nose-
mask attached to 1.5-2% isoflurane and 100-300 ml/min carrier gas source was placed 
over the animal’s nose for maintaining anesthesia. Either pure oxygen or air was used 
as carrier gas. The concentration and rate of the isoflurane flow was continually 
adjusted to maintain an adequate level of anesthesia. Under these conditions, mice 
could be under anesthesia for few hours. As an alternative to gas anesthesia, injectable 
anesthetics were used for viral injection procedures. Specifically, animals were 
anesthetized with a ketamine/xylazine mixture (ketamine 0.8 mg/kg and xylazine 0.1 
mg/kg), intraperitoneal (i.p.) injection. Vitamin A cream (Bausch & Lomb, 
Switzerland) was applied to prevent dryness of the eyes and damage to cornea. The 
level of anesthesia was monitored by closely observing the respiratory rate of the 
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animal and also by testing corneal and foot pinch withdrawal reflexes and absence of 
whisker movements. A deep anesthesia level was checked and confirmed before 
starting surgery/experiment and intermittently checked during surgical and 
experimental   procedures. The animals were placed on a heating pad to prevent 
anesthesia-induced hypothermia. Body temperature was monitored with a rectal probe 
and regulated to 37°C with the thermostat. 
 
4.2.2 Post-surgery treatment and monitoring 
Animals that recovered from a surgical procedure were treated with fluids and 
analgesics. 200 µl PBS was injected subcutaneously (s.c.) after surgery to maintain 
the water and electrolyte balance. Analgesic Rimadyl (Carprofen; 5 mg/kg body 
weight, s.c., effect last for 24 h) was applied directly before the operation, 24 h after 
the intervention and in a 24 h interval during the first week if required. Following any 
surgical procedure the animal's health and well-being was evaluated at least twice per 
day for the first two days. Thereafter, the animals were monitored daily and their 
condition was documented with the help of a score sheet (see Supplementary 9.2). In 
the case that the condition of an animal indicated problems (e.g. dehydration, wound 
infections) or behavioral abnormalities (such as lethargy, overly aggressive, motor 
deficits), that animal was again monitored at least twice per day and necessary actions 
were taken (e.g. analgesia, antibiotic treatment) until its condition had improved or a 
termination criterion was met.  
 
4.2.3 Preparation of thinned-skull and craniotomy 
Once anesthetized, animals were placed on an operating plate or a stereotactic 
apparatus. For preparation of a cranial window, the top of the animal’s head was 
sterilized with 70% ethanol and shaved. A midline incision of approximately 3 cm 
was made on the center of scalp, the soft tissue was removed and the skull was 
cleaned. To access to regions located more laterally (e.g. barrel cortex) muscles were 
bluntly dissected. For acute (terminal) experiments a thin metal plate was attached to 
the skull using dental acrylic cement. This metal plate was used for head fixation of 
anesthetized animals during the experiment and to create a chamber around the 
craniotomy, to hold the water immersion of the microscope objective. The area for the 
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cranial window was chosen (1 mm for thinned-skull and 2-4 mm for craniotomy). For 
thinned-skull the area of interest (somatosensory cortex) was thinned slowly using a 
high-speed dental drill. Drilling was intermittently stopped and drill bit dipped in 
normal rat Ringer (NRR) solution (135 mM NaCl, 5.4 mM KCl, 5 mM Hepes, 1.8 
mM CaCl2; pH 7.2 with NaOH) to minimize heat-related tissue injury. The drilling 
was continued until the skull was 20-30 µm thick and the underlying pial vessels were 
visible through the wet thinned skull. Great care was taken not to put any pressure on 
the underlying brain the whole time and maximal effort was made to obtain a uniform 
surface for imaging.  
 
 
 
For craniotomy, area of interest (somatosensory cortex or barrel cortex) of 2-4 mm 
was chosen and margins were drilled with a high-speed drill. The drilling was stopped 
intermittently and the area washed with normal rat ringer to minimize heat induced 
tissue injury. The bone flap was carefully removed with fine forceps. Any bleeding 
usually stopped spontaneously, if not, the surface was washed with normal rat ringer 
until the bleeding stopped. For acute experiments, the cranial window was filled with 
agarose (type III-A, Sigma, Buchs, Switzerland; 1% in NRR) and covered with a 
cover glass to dampen the tissue pulsations induced by heartbeat. For long-term 
repeated imaging a different head post was implanted and a chronic cranial glass 
A B C
D E
Figure 4.1: Steps of craniotomy. A, fixing the mouse, B, incision and cleaning the scalp, C, 
visualizing the landmarks to find the area of interest, D, fixing of head plate and marking the edges 
of craniotomy, E, surface vessels on the brain after removal of bone flap  
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window was prepared (see below, 4.2.4 and 4.2.5). Following the surgical preparation 
the animal was transferred to the experimental setup on a holder with heating pad. 
The anesthesia was continued and the experimental measurements were performed.  
 
4.2.4 Mounting of a head post for head immobilization  
This procedure was used in chronic types of experiments, in which the animal after 
recovery from the initial surgery was further investigated in subsequent experimental 
sessions. During a short anesthesia period, a small (1.5 cm; <0.5 g) aluminum head 
post was secured to the skull with super glue and dental cement. In later experiment 
sessions this head post was clamped to a holder with a screw for fixation of the 
animal’s head (Fig. 4.1). The head post was custom made. Briefly, the skull was 
cleaned and light-curing dental bonding agent (GLUMA Comfort Bond, Heraeus 
Kulzer GmbH, Germany) was applied to the damp skull, allowing penetration into the 
bone. After the bonding agent was cured with blue light, moldable dental cement was 
applied to the bonding agent, covering the fixable arm of the head post and the entire 
surface of the exposed skull. The cement was also cured with blue light. This formed 
a rigid connection between the head post and the skull. Mice with head posts were 
housed individually. With ad libitum access to food and water, weight and general 
health status of the mice was maintained on a daily as described in post-surgical 
procedures section (see 4.2.2). Loosening of the head-post was a criterion for 
terminating the experiment (see 4.2.6). 
 
4.2.5 Preparation of chronic cranial windows  
For repeated imaging of the same volume of brain in mice, chronically implanted 
glass windows above the cortical region of interest were prepared using standard 
techniques (Holtmaat, et al. 2009, Tackenberg and Brandt 2009). This type of window 
preparation permits longitudinal studies of the morphology and function of identical 
cells in individual animals and thus provides highly valuable longitudinal information 
over several weeks. Preparation of a chronic window started with a craniotomy as 
described in 4.2.3. The dura mater was left intact. A manually cut 2-4 mm cover glass 
with smoothened edges was lowered into the open space, where the skull was 
previously removed. The cover glass was secured in place with a rim of light-curing 
Materials and Methods 
	  	   57	  
dental cement (Tetric Evoflow, Ivoclar Vivadent, Leichenstein). A final layer of light-
curing sealant (OptiGuard, Kerr Italia, Italy) was used to tightly seal the edge of the 
cover glass. The mice were allowed to recover from anesthesia and post-operative 
monitoring was performed and documented as described in 4.2.2. To permit stable 
imaging conditions, a recovery period of at least 10 days after the cranial window 
implantation was observed (Hofer, et al. 2009). During the recovery period the 
animals were monitored according to the general post-surgical procedures (see 4.2.2). 
In addition, the tissue properties and window quality were closely inspected under a 
stereoscope in the days following the surgery. If tissue or window conditions did not 
allow high-quality imaging after such a period, the experiment was terminated. In 
addition, obvious signs of tissue inflammation or deterioration were a criterion for 
terminating the experiment (see 4.2.6). Previous imaging studies (Hofer, et al., 2009) 
and our own experience indicated that cranial windows – once they have cleared up 
and stabilized - remained transparent and stable for prolonged time periods up to 4 
months. 
  
4.2.6 Termination criteria for recovery following surgery 
If one of the following criteria was met the experiment was terminated and the animal 
was euthanized by overdose of anesthesia. 
1. More than 10% weight loss compared to initial weight 
2. More than 50% increased breathing rate compared to normal for more than 24 
hours 
3. Obvious behavioral abnormalities for more than 24 hours (lethargy, overly 
aggressive, motor deficits, stereotypic behaviors) 
4. Loosening of implanted head-post 
5. End of treatment period of 8 weeks 
6. Low/No expression of the virus 
7.  Score less than 15 on the score sheet (Appendix) 
Out of 20 animals used for chronic experiments only 2 animals had to be euthanized.  
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4.2.7 Brain dissection, fixation and histological reconstruction   
At the end of an experiment the animal was euthanized with an overdose of Nembutal 
(6-8 mg/100g body weight, i.p.) or, after deep anesthesia with Nembutal, it was 
transcardially perfused with 4% paraformaldehyde (PFA) in phosphate buffer for 
brain fixation. The brains were carefully removed and stored for 0.5-1 d at 4°C in the 
fixative before transfer to 30% sucrose in phosphate buffer solution. If needed thin 
fixed tissue sections were cut on a microtome. Standard histological procedures, 
including immunohistochemistry, were used for microscopy. The brain sections were 
stored at -20°C in anti-freeze solution (0.5 M phosphate buffer with 30% ethylene 
glycol and 30% glycerol). 
 
4.2.8 Immunohistochemistry 
Paraformaldehyde-fixed and cryoprotected brains were cut in 40 µm thick slices at 
about -80°C using a microtome (Leica Jung HN40) and kept at -20°C in an anti-freeze 
solution (phosphate buffer 0.50 M in MilliQ water: ethyleneglycol: glycerol = 
1.3:1:1) until stainings were performed. All immunohistochemical stainings were 
done by using the free-floating method. Washing steps were carried out between all 
incubations using washing buffer (TBS pH 7.4 containing 0.2%Triton X-100) at RT.  
Slices were blocked for 1 hr at RT using blocking buffer (5.0% goat serum 5.0% 
donkey serum in washing buffer). Blocked slices were incubated overnight at 4°C 
with slight agitation in primary antibody incubation buffer (2.5% goat serum and 
2.5% donkey serum in washing buffer) containing the primary antibody/antibodies 
(see table 1). Subsequently, secondary antibody incubations were carried out for 2 
hours at RT. Slices were washed in washing buffer, mounted on chrom-gelatin-coated 
microscopy slides (Super-frost-plus, Menzel, Braunschweig, Germany) and glass-
covered using Hydromount® (National Diagnostics, Hull, UK). 
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4.3 In Vivo Labeling Procedures  
4.3.1 Viral gene transfer of genetically encoded markers and sensors 
We induced expression of genetically encoded indicators using viral transfections for 
labeling cell populations. We used viral constructs coding for fluorescent proteins 
such as green fluorescent protein (GFP) calcium indicators of the yellow cameleon 
family. In particular, we used Yellow Cameleon 3.6 construct coupled to Adeno-
Associated Virus 2 (AAV2) vector under chicken beta-actin (CAG) or human 
synapsin (h-syn) (Lutcke, et al. 2010) promoter (Figure 4.2). Our collaborators Hasan 
and Sebastian Kugler labs prepared the virus as follows. rAAV equipped with YC3.60 
under control of a human synapsin  or chicken beta actin promoter (Figure 4.2) was 
co-transfected with pDp1, pDp2 (ratio:3:1) helper plasmids in HEK293 cells (Hasan, 
et al. 2004, Wallace, et al. 2008). Seventy-two hours after transfection, HEK293 cells 
were collected and packaged viruses were released by repeated freeze-and-thaw on 
dry-ice-ethanol bath. Viruses were purified first on the iodixanol gradient and later by 
pre-casted 1 ml Heparin columns (Amersham) using FPLC (Kügler et al., 2007). 
Infectious virus titers were determined in primary neuron cultures and was 3 °— 108 
transducing units per microliter. Viral injections were performed in a brief (0.5 h) 
surgical session under isoflurane or ketamine/xylazine anesthesia (Cetin, et al. 2006). 
Only the virus was prepared by our collaborators, rest of the procedures were done 
independently. The anesthetized mice were placed in a stereotactic apparatus. A small 
burr hole was drilled over the region of interest, the barrel cortex (-1mm from Bregma 
and 3.3 mm lateral). A very thin glass capillary tip was guided to the area of injection 
and approximately 300 nl of 1 million copies virus-containing solution (with 20% 
mannitol) was injected through this small hole directly into the brain while 
maintaining a steady pressure of 50. The pipette was left in place for few minutes 
before slowly retracting it to reduce the spill over. The burr hole was closed with bone 
wax and the skin sutured. For long-term imaging experiments, a chronic cranial 
window was prepared a few days after the virus injection in a separate anesthesia 
session (see 4.2.5). Sufficient levels of expression were reached within 1-3 weeks 
following the virus injection. 
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We injected 14 mice with CAG promoter and 6 mice with h-syn promoter. Out of 14 
mice injected with CAG promoter; 4 mice dropped out of study as they died before 
imaging started, 6 windows cleared up for imaging and 4 more windows did not. Out 
of 6 mice injected with h-syn promoter, 4 windows cleared up for imaging and 2 did 
not. See supplementary for detailed table of injected mice.  
 
4.3.2 Labeling of brain beta-amyloid plaques in vivo 
Beta-amyloid plaques in living transgenic mice were labeled with Methoxy-X04, a 
kind gift from Prof. Klunk, University of Pittsburgh. Methoxy-X04, discovered in 
2002 by Prof. Klunk, is a derivative of Congo red and Chrysamine G (Klunk, et al. 
2002). Methoxy-X04 (5 mg/kg) was injected i.p. a day before each imaging session. 
Being highly lipophilic it readily crosses the blood brain barrier and stains both beta-
amyloid plaques and cerebrovascular amyloid with good specificity (Klunk, et al. 
2002). Two protocols were used for injecting Methoxy-X04.  
 
a) 5 mg/ml Methoxy-X04 in 10% DMSO, 45% propylene glycol and 45% PBS 
and 5 mg/kg was injected as described in Klunk, et al. 2002. 
b) 10 mg of Methoxy-X04 was dissolved in 1 ml DMSO. 10 µl of this solution 
was dissolved in 20 µl of Cremophor EL and then finally dissolved in 270 µl 
of PBS, sonicated for 2 min and injected immediately. The amount of 
Methoxy-X04 injected was about 3 mg/kg. This protocol was obtained by 
Figure 4.1: Construction of YC3.60. The indicator consists of a circular permuted Venus 173 
variant  (cpVenus 173) as a yellow fluorescent protein (YFP) FRET partner of cyano fluorescent 
protein  (CFP), which are joined by calmodulin and M13. 
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personal communication with Prof. Bacskai (Massachusetts General Hospital, 
Boston, MA).  
 
4.3.3 Intravenous injection of fluorescent markers for labeling of blood vessels 
For visualization of the vasculature, we injected fluorescent dyes into the tail veins 
during anesthesia (Kleinfeld, et al. 1998). To avoid rapid dye loss due to clearance in 
the kidney dextran-conjugated fluorescent dyes including Fluorescein-dextran or 
Texas Red-dextran (molecular weight 70,000 Da, Invitrogen, Switzerland) were used. 
Tail veins in anesthetized mice were dilated by heat application (IR lamp or warm 
solution). The end of the tail was softly clamped and a bolus of dye-containing 
solution (5% w/v Ringer solution; 0.1 ml) was injected using a 29 G needle attached 
to a small syringe.    
 
4.3.4 Topical application of fluorescent markers  
Various markers are available that stain selected cell populations including astrocytes 
in a more or less specific manner upon topical application on to the brain surface. 
This procedure was carried out in anesthetized mice after craniotomy before 
application of the cover glass. 50 µl of dye-containing solution was applied to the 
exposed cortical surface. Penetration of the dye into the brain tissue was accelerated 
by cutting a small slit into the dura with the cutting edge of a needle tip. This type of 
labeling was for example used for specific staining of astrocytes with the red 
fluorescent dye sulforhodamine 101 (Nimmerjahn, et al. 2004). Brief application of 5-
10 min of 50 µM SR101 was sufficient to obtain bright staining of the astrocytes in 
red channel (645 nm). Subsequently, the tissue was rinsed with rat ringer solution to 
remove the excess dye.  
 
4.4 Imaging Procedures 
4.4.1 Functional mapping using intrinsic signal imaging  
Sensory regions in brain are organized anatomically reflecting the major inputs 
received from peripheral sensory organs. For example, distinct cortical columns of 
about 0.4 mm diameter are responsible for the initial cortical processing of 
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movements by each facial whisker in the primary somatosensory area S1, the ‘barrel 
cortex’ (Petersen 2003) (see 3.2.3). Before applying measurements with high-
resolution two-photon imaging, we performed functional mapping of the barrel cortex 
to verify the exact locations where exactly high-resolution measurements are to be 
performed. For this purpose we used intrinsic signal imaging (ISI; Orbach, et al. 1985, 
Kerr, et al. 2007). ISI does not require labeling and it was done during anesthesia 
either through a previously acutely prepared (see 4.2.3) or chronically implanted glass 
window (see 4.2.4). For functional mapping using ISI the anesthetized animal was 
placed on a heating pad in a holder under the custom built two-photon microscope 
(for details see 4.4.2). The cranial window was illuminated with red light and the light 
reflected from the brain surface was imaged onto a sensitive camera system 
(Olympus, Tokyo, Japan). Upon whisker stimulation (for details se 4.4.4), the blood 
flow to the particular area increases, resulting in the absorption of red light and 
thereby decreasing the signal intensity (Orbach, et al. 1985). By comparing the 
stimulus-evoked intrinsic signal with a baseline measurement without stimulation, it 
was possible to delineate individual barrel corresponding to individually stimulated 
whiskers. The resulting functional map was related to barrel cortex areas using the 
pattern of large and medium-sized surface blood vessels as landmarks. The individual 
whisker to be stimulated was chosen by matching up the area of viral expression with 
the intrinsic signal in the cognate area.    
 
4.4.2 In vivo two-photon microscopy 
In vivo imaging was performed with a custom-built two-photon-laser-scanning 
microscope equipped with a Ti:sapphire laser system (MaiTai HP, Spectra-Physics, 
Santa Clara, USA) tuned to 850 nm wavelength as the light source (about 100 fs 
output, 1 W power). The laser intensity was adjusted with Pockle’s cell (Conoptics, 
Danburry, USA) such that none of the channels weren saturated. The microscope was 
equipped with two galvanometric scan mirrors (Model 6210; Cambridge 
Technologies, Lexington, USA) for scanning the specimen in the x–y axis, and a 
piezoelectric focusing element (P-725.4CD PIFOC, Physik Instrumente, Karlsruhe, 
Germany) for z-scanning along the optical axis. The area to be imaged was initially 
identified by using a 10x air objective (NA 1; Olympus, Tokyo, Japan) and later a 40x 
water immersion objective (NA 0.8; Olympus, Tokyo, Japan) was mounted onto the 
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piezo element, focusing the laser beam into the cortical imaging area. Data was 
acquired by a custom-written software (LabView, National Instruments Corporation, 
Austin, TX, USA). The fluorescence generated by the two-photon excitation was 
collected through the same microscope objective and detected in one or more spectral 
imaging channels corresponding to emission spectra of the fluorophore i.e., 542 nm 
for green/yellow, 475 nm for blue and 610 nm for red, depending on the specific 
fluorophore used in the experiment.  
 
4.4.3 Longitudinal imaging using cranial windows over several weeks 
We applied chronically implanted cranial windows (see 4.2.5) to repeatedly image 
identical brain structures by using two-photon microscopy. Longitudinal imaging was 
started 15-21 days following the window preparation. Mice were re-anesthetized and 
then re-imaged under the two-photon microscope for up to 8 weeks. The animal was 
placed under the microscope and imaging was performed as described in 4.4.2. The 
identical areas in the neocortex and the identical beta-amyloid plaques and cells were 
identified across sessions based on landmarks provided by the blood vasculature 
pattern at the brain surface; which had been documented during the initial imaging 
session. 3-5 imaging locations were chosen for each animal and the identical locations 
were reimaged during every single imaging session. The integrity of the windows was 
monitored before starting an imaging session. If needed, additional dental cement or 
sealant was applied in order to fix the windows. With chronic windows we performed 
functional imaging of the identical neurons over extended time periods of several 
weeks or months, as long as imaging conditions permitted optimal microscopy. Long-
term imaging over many weeks allowed a significant reduction in the number of 
experimental animals, because the obtained data were less variable and the same 
preparation was used for several research questions. At the end of the imaging 
sessions, the mice were returned to their home cages. Imaging sessions were repeated 
with intervals of 2-3 days. At later phases of experiment, sessions were repeated about 
once every week. At the end of the last imaging session, mice were sacrificed and 
brain tissues processed as described in 4.2.8.  	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4.4.4 Sensory stimulation and optical recordings 
Whisker stimulations were done by wiggling either individual or multiple facial 
vibrissae on the contralateral side of the craniotomy in various directions using a 
piezo-electric deflector (Brecht, et al. 2003). Whiskers that were mapped earlier 
(4.4.1) were stimulated at a frequency of 20 Hz for 0.5 s, repeated every 5 s for 15 
times for 5 cycles. Each cycle of evoked-response was preceded by a cycle of 
spontaneous activity. Thus there were 5 cycles of spontaneous and evoked-response 
for each location. Approximately 20-30 min were needed for imaging one location 
and each mouse with 4-5 locations required 2-2.5 hours of imaging time.  
4.4.5 Time-lapse imaging of microglia 
Time-lapse imaging of microglia was done only in APP/PS1dE9;CX3CR1 and 
APPsweArc;CX3CR1 transgenic mice. Areas with beta-amyloid plaques were 
selected and imaged for a period of 6-7 hours. 40-60 µm stacks of the plaque area 
were acquired every 2 min. Rest of the procedure was same as in 4.4.3. 
4.5 Immunotherapy 
4.5.1 Intracerebral application of anti-Abeta antibodies 
Direct application of the anti-Aß antibody (in-house generated anti-Aβ IgG2a targeted 
against fibrillar Aβ) into the cortex was done by microinjection with 10-30 µm 
diameter glass micro-pipettes. This procedure was carried out in anesthetized animals. 
The micro-pipette was loaded with 5 µl of 1 µg/µl of the antibody. The tip of the 
micro-pipette was navigated at 45° angle under the visual control to the target area 
through a cranial window (4.2.3), and antibodies were injected over 4-5 minutes. This 
type of loading is also known as the multi-cell bolus loading technique (Stosiek, et al. 
2003). The micro-pipette was then gently retracted. The craniotomy was then 
completed as described earlier (4.2.3) or a chronic window was implanted (4.2.5). For 
some experiments, the antibody was conjugated to a fluorescein or texas red and bulk-
loading was done around beta-amyloid plaques.  
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4.5.2 Systemic passive immunization 
Passive immunization of 7-month-old APPsweArc mice was done by i.p. injections of 
5 mg/kg anti-Aß antibody injection once a week for 12 weeks period. i.p. injections of 
anti-Aβ antibody, which was a chimeric monoclonal antibody consisting of human 
variable domains and mouse IgG2a constant regions. It selectively recognized 
aggregated forms of Aß1-40 and Aß1-42 with high-affinity (low nM range) (Biscaro, 
et al. 2009). The control mice received the same amount of vehicle (PBS).  
 
4.6 Data analysis  
The initial imaging data processing was done offline with ImageJ software (version 
1.42, NIH, USA, http://rsbweb.nih.gov/ij/). For morphological data and time-lapse 
imaging data, the raw data were converted into stacks and maximal intensity Z 
projections were created. Subsequently, one plane was chosen and images of the same 
plane from different stacks were collected and a movie was created with all the 
images. The X, Y alignment was corrected with a custom written macro by Prof. 
Helmchen. The intrinsic imaging data was analyzed with a custom written software 
(LabView, National Instruments Corporation, Austin, TX, USA). The functional data 
were analyzed with MATLAB R2010b version (Mathworks) using in-house custom 
written script written by Dr. Lütcke. The ROIs (cell bodies of neurons) were manually 
drawn using ImageJ. It was made sure that all the spots had exact same number of 
ROIs. These ROIs were later analyzed for calcium transients. The calcium signals 
were expressed as ΔR/R= (R-R0)/R0 Where R the ratio of background-corrected CFP 
and YFP fluorescence, i.e. R=FCFP/FYFP and R0 is the baseline or pre-stimulus ratio 
value. Identification of spontaneous or evoked events as well as estimation of the 
number of action potentials underlying observed ΔR/R calcium signals was done with 
the peeling algorithm (Grewe, et al. 2010) assuming a reasonable single action 
potential-evoked calcium signal waveform for YC3.60 (Lütcke, et al. 2010). The 
neuropil signals were calculated from the whole imaging frames. The spontaneous 
activity rate was calculated as number of events per second. To measure the evoked 
activity due to whisker stimulation, the activity 1 second before and after the stimulus 
were calculated. The difference was the whisker stimulus-evoked activity.  
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The results section is divided in three major parts. In the first part, I present several 
technical issues regarding the establishment of chronic in vivo imaging in neocortex 
of mice. In the second section, several experiments exploring the possibilities to 
further study microglia-plaque interaction are presented. Finally, in the third section, a 
first study applying genetically-encoded calcium indicators for long term repeated 
study of neuronal activity in pre-plaque phase of Alzheimer’s disease is presented. 
 
5.1 Standardization of chronic imaging protocols 
5.1.1 Use of head post reduces movement artifacts 
 
One of the major issues in chronic imaging is minimization of movement artifacts, 
which are caused by breathing and heartbeat in the anesthetized animal (Helmchen 
and Denk 2005). Conventionally, the mice placed on a holder with ear bars (Figure 
4.1 A). However, this does not provide enough stability and leads to numerous 
movement artifacts (Figure 5.1). These movement artifacts were observed in 3 out of 
3 CX3CR1+/- mice imaged with ear bar fixation. It is very important to have as 
steady images as possible as movement artifacts interfere with analysis of images. 
Dynamic and fine structures such as microglia are affected by very small movements 
(Figure 5.1). 
  
           
Figure 5.1: Movement artifacts on time-lapse imaging of microglia without head posts. The 
images are examples of single frame of a time-lapse movie of 20 min in CX3CR1+/- mice. The 
green and yellow arrows indicate the changes in microglia morphology due to movement artifacts. 
Large movement artifacts are seen, which make it difficult to localize the microglia. Scale bar=20 
µm 
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These movement artifacts were reduced to an acceptable level with the use of head 
posts (Figure 5.2).  I therefore concluded that head-posts provide improved stability 
and decided to use head posts for chronic imaging experiments.  
 
           
     
Custom made head posts were used for all the chronic imaging experiments. The 
reduction in movement artifacts was uniform and provided good quality images.  
 	  
5.1.2 Comparison between imaging through thinned-skull and craniotomy in 
living mice 
Technical differences in the cranial window preparation can have a major impact on 
the imaging quality. We compared thinned-skull and craniotomies for our 
preparations as it is currently debated if thinned-skull is less invasive than 
craniotomies (Drew, et al. 2010, Grutzendler and Gan 2006, Xu, et al. 2007). 
Thinned-skull preparations are shown to cause less microglia and astrocyte reaction in 
the imaging area and affect dendritic turnover (Drew, et al. 2010, Grutzendler and 
Gan 2006, Xu, et al. 2007). In the field of Alzheimer’s disease both thinned-skull and 
craniotomies have been used with equal efficacy (Burgold, et al. 2011, Christie, et al. 
2001, Hefendehl, et al. 2011, Yan, et al. 2009). Our data show that craniotomies were 
better for chronic imaging purposes. They were easy to prepare, needed almost no 
Figure 5.2: Time-lapse imaging of microglia with head posts. The images are examples from single 
frame of a time-lapse movie of 5 hours in APP/PS1dE9;CX3CR1+/- mouse. The images are stable, the 
white and yellow arrows indicate no changes in microglia morhphology. Blue: plaques, Green: 
microglia and Fluorescein dextran labeled blood vessels. Scale bar=50 µm 
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maintenance and stabilized windows remain transparent for many weeks up to several 
months. In contrast, thinned-skull preparations require more technical skill, along 
with re-thinning before each imaging session, which in some cases cause brain injury 
and lead to termination of the experiment. For imaging finer brain structures including 
the microglial processes, thinned-skull preparations were inadequate because of poor 
image quality compared to craniotomies (Figure 5.3). To achieve one goal of one of 
the experiments, time-lapse imaging of microglia surrounding beta-amyloid plaques, 
it was very important to visualize microglial processes clearly. Thus, both from a 
technical perspective as well as for reasons of better image quality, we chose 
craniotomies for most of the experiments.   
 
 
5.1.3 Improvements to the chronic craniotomy window imaging technique 
For long-term imaging the quality of the chronic cranial window is essential. We 
therefore tested various modifications in order to optimize window quality. The 
following procedural modifications turned out to be useful 
 special light-curable dental cement, that can be readily molded was used to 
cure the edges of craniotomy in a step-wise manner 
 bonding agent on the wet skull to secure the head post and to make a durable 
bridge between skull and dental cement 
A B
Figure 5.3: Superior imaging quality of craniotomy as compared to thinned-skull preparation. (A):  
Max. intensity Z-projection (20 µm) image from thinned-skull preparation of a APP/PS1dE9;CX3CR1+/- 
mouse, showing beta-amyloid plaques in blue and GFP-expressing microglia in green. The cell bodies of 
microglia are seen clearly but it is difficult to see microglial processes. Scale bar= 20 µm. (B): Max. 
intensity Z-projection (40 µm) image from craniotomy of a APP/PS1dE9;CX3CR1+/- mouse, showing beta-
amyloid plaques in blue, GFP-expressing microglia and Fluorescein dextran labeled blood vessels in green. 
Here both the microglial cell bodies and processes are very easy to identify. Scale bar= 50 µm 
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 a sealant to ensure tight fitting of the cover glass around the edges of 
craniotomy 
 manually cut cover glass with smoothened edges to reduce any sort of injury 
to exposed brain surface 
 
The dental cement, bonding agent and sealant were all light-curable, and a blue light 
was used for this purpose. Typically the time needed to cure was between 20-60 s. As 
the dental cement was moldable, the edges of the cranial windows were cured in 2-3 
steps, applying different amounts of dental cement each time as needed. This 
provided flexibility to cover the windows in a systematic manner and eliminated the 
necessity of covering the whole craniotomy in a single step, and avoided the related 
complications including bleeding and tissue injury resulting in termination of the 
experiment thereby. 
 
There was a recovery period of few days up to 2 weeks before imaging sessions were 
started. During this recovery period the inflammatory reaction following the surgery 
subsided and the window cleared up for imaging. The cleared up windows stayed 
transparent for weeks to months (Figure 5.4). Slight bleeding occurring in few cases 
resolved spontaneously within in few days. In our hands about 50% windows cleared 
up for imaging purposes, which is slightly above the rates is described in the 
literature.  The ‘clean window’ was a window without any glial scar tissue formation 
or without any bleeding and through which the surface blood vessels were clearly 
visible under stereoscope.  
 
 
DENTAL CEMENT
Figure 5.4: Preparation of a chronic cranial imaging window in mouse. Left: Anesthetized 
mouse with a chronic cranial window and head post 60 days after implant. Right: Close-up of 
cortical surface visible through the cranial window.   
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5.1.4 Labeling of beta-amyloid plaques in living mice 
 
Methoxy-X04 is highly lipophilic and difficult to dissolve in aqueous physiologic 
buffers. Therefore, different solvents were used for two different protocols (Figure 
5.5). With DMSO and propylene glycol protocol, only about 50% of Methoxy-X04 
was dissolved and thus, the labeling of plaque was not extensive (Figure 5.6 A). With 
the Cremophor EL, DMSO protocol, 100% Methoxy-X04 was dissolved and resulted 
in extensive labeling of beta-amyloid plaques (Figure 5.6 B).  Therefore, this protocol 
was used for all Methoxy-X04 injections.  
 
 
 
 
Methoxy-X04 is widely used for in vivo labeling of beta-amyloid plaques. It needs to 
be injected intraperitoneally prior to every imaging session (Bacskai and Hyman 
2002). However, there are some reports of using it once in a week after a loading dose 
for first imaging session with satisfactory plaque labeling (Burgold, et al. 2011).  
 
 
 
 
 
 
 
A B
Figure 5.5: Improved beta-amyloid plaque labeling with dissolved in Cremophor EL (A) 
Protocol with DMSO and propylene glycol shows sparse plaque labeling in 9 month-old 
APP/PS1dE9 mouse. Blue: plaque, Red: Texas red dextran labeled blood vessels. Scale bar= 30 µm 
(B) Protocol with DMSO and cremophor EL shows extensive plaque labeling in 9 month-old 
APP/PS1dE9 mouse. Vascular amyloid is also stained (arrow). Blue: plaque, Green: Fluorescein 
dextran labeled blood vessels and GFP-expressing microglia. Scale bar= 50 µm 
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5.2 Various techniques to study microglia-plaque interaction  
After establishing the chronic imaging protocols, we tested these protocols for their 
stability and viability during long imaging sessions, which are vital for obtaining high 
quality images during longitudinal imaging.  
 
5.2.1 In vivo appearance of typical parenchymal and vascular plaque 
The parenchymal plaques were seen throughout the imaging volume in all imaged 
layers of cortex, whereas vascular cerebral amyloid angiopathy (CAA) was seen 
mainly in the medium-sized arterioles (Figure 5.6 A). Different types of parenchymal 
plaque morphologies were also seen. APP/PS1dE9 mice showed mainly compact 
amyloid deposits (Figure 5.6 B) whereas APPsweArc mice showed mainly diffuse 
amyloid deposits (Figure 5.6 C). 
 
 
 
 
In APP/PS1dE9;CX3CR1+/- mice, plaque  pathology was characterized by varying 
plaque size between 20-50 µm in Z-axis and 10-30 µm in X and Y axes (Figure 5.7). 
There were different tiers of microglia around the plaque. Usually on a single plane 5-
8 microglia were seen around a single plaque, which was consistent with earlier 
reports in APP/PS1;CX3CR1 +/- mice (Bolmont, et al. 2008) (Figure 5.7). Thus, in 
3D there would be 20-35 microglia around a typical beta-amyloid plaque.  
B
A B C
Figure 5.6: Different types of plaques. Blue: plaque, Green: Fluorescein dextran labeled blood 
vessels. (A) Vascular plaque in a 12-month-old APPsweArc mouse (arrows). Max. intensity Z-
projection image of 20 µm stack. Scale bar= 50 µm (B) Compact plaques in 12-month-old 
APP/PS1dE9 mouse. Max. intensity Z-projection image of 40 µm stack. Scale bar= 50 µm  
(C) Diffuse plaques in 15-month-old APPsweArc mouse. Max. intensity Z-projection of 30 µm 
stack. Scale bar= 30 µm 
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5.2.2 Plaque targeted antibody application 
Any intervention in the brain causes some damage to the tissue and it is important to 
use techniques, which are as less invasive as possible, and cause as little damage as 
possible to the tissue. In this experiment we tested if bulk loading of anti-Aß antibody 
causes any immediate damage to the tissue. The technique of bulk loading was used 
to inject a small amount of antibody (approx. 1 µg) into the area surrounding a plaque 
(20-30 µm distance from a plaque). A baseline stack was acquired and stack after the 
injection was acquired. There was no tissue injury/edema after the injection (Figure 
5.8). The dextran is cleared from blood vessels over time (Figure 5.8 B) and there is 
slight change in imaging plane between A and B.  
 
 
 
 
 
 
 
 
 
 
 
A B C
Figure 5.7: Zoomed in plaque. Two plaques zoomed in 15-month-old APPsweArc mouse showing 
different planes of a plaque. A, B and C, are 5, 15 and 30 µm deep in the Z-axis. Many microglia are 
seen surrounding the plaques at each level.  Blue: plaque, Green: microglia and Fluoresecin dextran 
labeled blood vessels. Scale bar= 30 µm 
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The same area was imaged for three consecutive days and the size of the same plaque 
(white arrow) was followed (Figure 5.9). It turned out to be important to use same 
microscope settings (zoom, laser intensity) each day in order to ensure that these 
factors did not confound the results. Even when these factors were constant, the 
morphology of the plaques itself was inconsistent. We compared the size of one 
plaque (white arrow) with another plaque (yellow arrow). Same plaques were imaged 
over 3-7 days in 3 APP/PS1dE9;CX3CR1+/- mice. Thus, I successfully established 
repeated chronic 2-photon imaging of the same plaques over days and I could 
demonstrate that the combination with antibody application. The preliminary data 
show that the same plaques can be found in imaging sessions following antibody 
application, however the data set is too small (and the time duration perhaps too short) 
to make any statement on affect on plaque size. 
 
 
 
 
 
 
 
A B
Figure 5.8: Bulk loading of antibody does not cause any tissue injury Blue: plaque, Green: 
Fluorescein dextran labeled blood vessels and microglia (A) Max. intensity Z-projection image from 
200 µm baseline stack before the antibody application (B) Max. intensity Z-projection image from 
200 µm stack acquired after the antibody application. No tissue injury (edema, bleeding) is seen. 
The dextarn has been cleared from the blood vessel. Both parenchymal and vascular plaques are 
visible. Scale bars= 50 µm 
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5.2.3 Application of fluorescently tagged antibody  
 
Even though it has been almost a decade since immunotherapy was discovered as a 
therapeutic approach for AD (Bacskai, et al. 2001), the understanding of the essential 
mechanism underlying its effects is still incomplete (Brody and Holtzman 2008). It is 
important to visualize the antibody to understand its interaction with the plaque and 
neighboring cells. Therefore we conjugated the antibody to the fluorescent molecules 
including Cy-2 (Figure 5.10 A) and Texas red (Figure 5.10 B) and direct intracerebral 
injection of the conjugated antibody in the periphery of amyloid plaques. These were 
acute experiments and chronic imaging of these mice was not done. 
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Figure 5.9: Serial imaging of same plaque over days after antibody application. Blue: plaque, 
Green: Fluorescein dextran labeled blood vessels and microglia. Serial imaging of plaque 1 (white 
arrow) on Day 1 (A), Day 2 (B) and Day 3 (C) after antibody application shows a reduction in 
plaque size. Plaque 2 (yellow arrow) was used as a control plaque. Scale bars= 50 µm (D) shows 
changes in the size of plaque 1 measured on a Z-axis and (E) shows changes in the size of plaque 2 
using same protocol. A reduction of size of plaque 1 is seen whereas size of plaque 2 does not 
reduce. In both D and E, X-axis is number of frames and Y-axis is fluorescence units.  
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As the plaque was imaged in blue channel and microglia in green channel, we chose 
Texas red tagged antibody, which could be imaged in red channel thus making use of 
all existing imaging channels. For this reason we did not choose Cy-2 as the green 
channel was required to image microglia. After the application of Texas red tagged 
antibody into the cortex of 12-month-old APPsweArc mice (n=2), the same plaque 
was imaged over hours (Figure 5.11) and later on consecutive days (Figure 5.12). 
Time-lapse imaging did not show immediate changes in plaque size (Figure 5.11). On 
chronic imaging it was seen that the antibody bound to plaque started to disappear 
around day 3. By day 7, almost no antibody was bound to the plaque (Figure 5.12). 
This could be due to decay of the fluorescent dye itself and clearance of the antibody. 
However, no change in plaque size was seen (Figure 5.12).  
 
 
 
 
 
 
 
 
A B
Figure 5.10: Fluorescent tagged antibody. (A) Cy-2 tagged antibody injected intracerebrally in 
14-month-old APPsweArc mouse. Blue: plaque, Green: antibody, blood vessels. Scale bar= 30 µm 
(B) Texas red tagged antibody injected intracerebrally in APP/PS1dE9 in 12-month-old mouse. 
Red: plaque, Green: microglia. Scale bar= 30 µm 
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5.2.4 Time-lapse imaging of microglia after treatment with tagged and untagged 
antibody 
The next step was to inject Texas red tagged antibody intracerebrally in 12-month-old 
APPsweArc;CX3CR1 +/- mice (n=3) to study the response of microglia within hours 
after antibody application (Figure 5.13). We saw the uptake of plaque-antibody 
complex by microglia around the plaques in one of the mice (Figure 5.13 Panel 2, 
arrow).  
 
In the next set of experiments, we injected untagged antibody into the brains of 12-
month-old APP/PS1dE9;CX3CR1 +/- mice (n=2). Same area was imaged over a 
period of hours on Day 1 and serially imaged on following days (up to 3 days). Figure 
5.14 and 5.15 show recruitment of new microglia in the periphery of plaque where the 
antibody was injected. The cells reorganized and were seen to be activated microglia 
after 24 hours. Unfortunately, there was bleeding in the cranial window of mice used 
for experiment in 5.14 after 24 hours and subsequent imaging could not be done.
15 min 30 min 45 min 60 min
90 min 2 hr 3.5 hr 5 hr
A B C D
E F G H
Figure 5.11: Time-lapse imaging after texas red tagged antibody application Images A-H show 
max. intensity Z-projection of 20 µm of 12-month-old APPsweArc mice. Red: plaque, Green: 
Fluorescein dextran labeld blood vessels and microglia. No change in plaque size was observed in 
the first 6 hours. Scale bar= 50 µm 
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Figure 5.12: Chronic imaging in texas red tagged antibody injected mouse. Images are 
max. intensity Z-projections of 20 µm of 12-month-old APPsweArc mice. A gradual decrease 
in the antibody bound to the plaque was observed (red channel), whereas there was no change 
in the size of plaques was observed (blue channel). Scale bar= 30 µm 
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Figure 5.13: Time lapse imaging in APPsweArc;Cx3CR1 +/- mice after Texas red tagged 
antibody application. Red: plaque, Green: microglia Images A and D are 30 min, B and E 90 
min and C and F 4 hours following antibody application. Each image is from a single frame. 
The arrows show the uptake of plaque-antibody complex by microglia. Scale bar= 30 µm 
Figure 5.14: Time 
lapse imaging in 
APP/PS1dE9;CX3CR
1 +/- mice after 
untagged antibody 
application.  Blue: 
plaque, Green: 
microglia. Images are 
single frame and time 
points represent time 
elapsed after antibody 
application. 
Recruitment of new 
microglia is seen in the 
periphery of the 
plaque. The new cells 
are activated microglia 
are seen in subsequent 
days (24, 48 and 72 
hours). Scale bar= 20 
µm 
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2 h 2.5 h 3 h 3.5 h
4 h 4.5 h 5 h 6 h
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3 h 4 h
Figure 5.15: Time lapse imaging in APP/PS1dE9;CX3CR1 +/- mice after untagged antibody 
application.  Blue: plaque, Green: Fluorescein dextran labeled blood vessels and microglia. Images 
are single frame and time points represent time elapsed after antibody application. Recruitment of 
new microglia in the periphery of the plaque was observed. The new cells are activated microglia 
are seen within few hours after antibody application. Scale bar= 20 µm 
Figure 5.16: Time lapse imaging in APP/PS1dE9;CX3CR1 +/- mice after PBS application.  Blue: 
plaque, Green: microglia. Images are single frame and time points represent time elapsed after PBS 
application. No changes are seen. Scale bar= 20 µm 
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PBS injection was used as the control and the imaging protocol was the same. 12-
month-old APP/PS1dE9;CX3CR1 +/- mice (n=2) were used. The time-lapse imaging 
showed less recruitment of microglia in the area surrounding the plaque (Figure 5.16).  	  
Thus, with the techniques of time-lapse and chronic imaging we were able to image 
microglia and beta-amyloid plaques. Although local anti-Aß antibody application did 
not show plaque clearance, we observed vigorous recruitment of microglia to plaque 
periphery after local application of anti-Aß antibody compared to PBS injection. 
These results although preliminary are promising in the field of plaque-microglia 
interactions.  
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5.3 Imaging Cortical Neuronal Activity in Transgenic Models of 
Brain Amyloidosis 
5.3.1 Expression of the genetically encoded calcium indicator: YC3.60 
YC3.60 is a genetically encoded calcium indicator (Lutcke, et al. 2010, Nagai, et al. 
2004). The indicator cloned in to rAAV was expressed under either one of the two 
promoters: the chicken ß-actin promoter  (CAG) or human synapsin promoter (h-syn). 
YC3.60 expressed under the CAG promoter labeled about a small percentage of 
neurons (Figure 5.17 A) while YC3.60 expressed under the h-syn promoter, labeled 
majority neuronal population (Figure 5.17 B). On the other hand, YC3.60 expressed 
under the CAG promoter resulted in better labeling of axons as compared to YC 
expressed under the h-syn promoter. 
 
 
The YC3.60 expression was mainly seen in superficial layers of the cortex up to 350 
µm in depth, with some labeling of axons (Figure 5.18 A-C).  
 
A
BA
Figure 5.17: Expression of YC3.60 in layer 2/3 of mouse neocortex under CAG (A) and h-syn (B) 
promoters after 6 weeks of injections.  While the percentage of neuronal labeling is higher in h-syn 
promoter, axonal labeling is more prominent with CAG promoter.  Scale bar= 20 µm 
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The expression of the indicator was very stable over weeks to months in 9 animals, 
allowing the identification and imaging of exact same cells over time (Figure 5.19 A-
C). In these experiments, the indicator was stable up to 4 months in 2 mice, up to 3 
months in 5 mice and up to 9 weeks in 2 mice. Four to five imaging locations were 
selected for each mouse based on the anatomy of surface vessel patterns. The same 
locations were identified on each imaging session and aligned in the same X, Y and Z 
co-ordinates. Optimal laser intensity was ensured between different imaging sessions.  
 
5.3.2 Measuring calcium transients 
YC3.60 reports the FRET change caused by conformational changes in the linked 
CFP-YFP pair, which, in turn is trigged by increase in free intracellular calcium 
levels. The fluorescence of the acceptor protein YFP, increases while the fluorescence 
of donor protein CFP, decreases. This percentage change in fluorescence intensities of 
YFP/CFP ratio, expressed as ∆R/R, was used as measure of neuronal activity because 
calcium influx in neurons mainly is observed following action potential generation. 
50 um 150 um 300 umA B C
20100923 20101007 20101029
A B C
Figure 5.18: Expression of YC3.60 under h-syn promoter in the superficial layers of cortex 6 
weeks after virus injection. A, 50 µm, B, 150 µm, and C, 300 µm from the surface. Scale bar= 50 
µm 
Figure 5.19: Stable expression of YC3.60 indicator. Same cells (arrows) are seen on different 
imaging days, spanning over a month (A, B, C). Similar fluorescence levels were seen.  Scale bar= 20 
µm 
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Figure 5.20 shows an example of YC3.60 ∆R/R calcium transients, which was 
calculated by a MATLAB algorithm (see section 4.6). Our goal was to measure 
calcium signals in pre-plaque phase of Alzheimer’s disease and study how it is 
modulated by therapeutic intervention such as immunotherapy. We thus divided the 
animals into wt control, antibody treated and vehicle treated groups. We measured 
spontaneous activity, whisker-evoked response and neuropil activity in these groups.  
  
 
5.3.3 Spontaneous Activity 
We first assessed spontaneous activity in the barrel cortex of mice in wt control, 
antibody treated and vehicle treated groups groups. Each measurement trial consisted 
of frame scan recording of number of events over recording time of 76.8 s duration. 
We quantified the number of events over this recording period. The value of 0.1 Hz is 
equivalent to 1 event in 10 seconds. All values are expressed as mean + standard 
deviation. The average rate for antibody treated group (n=177 cells in 3 mice) was 
0.14 + 0.08 Hz, for vehicle treated group (n=255 cells in 3 mice) was 0.08 + 0.06 Hz 
and for wt control (n=132 cells in 3 mice) was 0.16 + 0.11 Hz. Statistical significance 
(p<0.05) was seen between the antibody treated and vehicle treated; between antibody 
treated and wt control; and between vehicle treated and wt control groups (Figure 
5.21).  Figure 5.22 shows examples of spontaneous events in a vehicle-treated mouse.  
  
 
5 s
10%
Figure 5.20: Calcium transients reported by YC 3.60. The grey lines in the background indicate the 
time of whisker stimulation. Each black tick indicates one event as calculated by the algorithm.  
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Figure 5.21: Comparison of spontaneous activity in Ab-treated, vehicle-treated and control mice. 
The values are mean + SD. The Y-axis represents Hz. Statistical significance (p<0.05) was seen 
between the antibody treated and vehicle treated; between antibody treated and wt control; and 
between vehicle treated and wt control groups.  
 
 
Figure 5.22: Sample Spontaneous Activity.  Each trace represents activity of individual cell in a 
vehicle-treated mouse. There was no whisker stimulation. Each black tick represents a detected event. 
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Next we analyzed whether we could observe a change in spontaneous activity in the 
longitudinal imaging sessions. Chronic imaging of the same cells was done and 
comparisons made over 8 weeks. The first imaging session was considered as baseline 
value and weekly measurements were made in three groups. The table below shows 
values for each group. The values are expressed as mean + SD Hz. 
 
 Ab-treated Vehicle-treated Wt control 
Baseline 0.08 + 0.07 0.14 + 0.16 0.15 + 0.15 
1 week 0.10+ 0.09 0.07+ 0.06 0.13 + 0.13 
2 weeks 0.13 + 0.09 0.11 + 0.08 0.16 + 0.15 
3 weeks 0.17 + 0.20 0.13 + 0.12 0.12 + 0.08 
4 weeks 0.12 + 0.11 0.12 + 0.13 0.25 + 0.13 
5 weeks 0.18 + 0.12 0.12 + 0.10 0.20 + 0.10 
6 weeks 0.19 + 0.15 0.08 + 0.05  
7 weeks 0.17 + 0.11 0.06 + 0.04  
8 weeks 0.20 + 0.11 0.06 + 0.03  
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Figure 5.23: Spontaneous activity over weeks. The values are mean + SD. The Y-axis represents 
Hz. Statistical significance (p<0.05) is seen between the antibody treated and vehicle treated (blue 
stars) groups at all time points except 3 and 4 weeks; between antibody treated and wt control (red 
stars) groups at baseline, 1 wk and 4 wks; and between vehicle treated and wt control (green stars) 
groups at all time points except baseline.  The dashed lines represent the linear regression for the 
time points.  
Table 5.1: Spontaneous event rate of Ab-treated, vehicle-treated and wt control over weeks. The 
values are given in units of Hz as mean + SD. 	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Over the course of weeks, the spontaneous activity of Ab-treated group increased and 
followed the trend of wt control whereas the response of vehicle-treated group 
decreased. The linear regression analysis shows that the response of Ab-treated 
groups at baseline is similar to vehicle-treated group and after antibody treatment it 
follows the trend line of wt control groups indicating recovery of spontaneous 
response in antibody-treated groups (Figure 5.23). First of all, the data demonstrate 
that repeated functional assessment is possible. Secondly, interpretation and statistical 
analysis is tricky but an interesting trend in Ab-treated versus vehicle-treated is 
visible. This trend should be further examined in larger animal groups and under even 
better controlled conditions. 	  
 
5.3.4 Evoked Activity in AD and wt control mice 
 
Next, we measured calcium transients in response to whisker stimulation in barrel 
cortex. We first identified the principal whisker corresponding to area of viral 
expression. Table 5.2 lists the whiskers that were stimulated for each mouse. The 
evoked activity was measured in all the three groups. We quantified the rate of 
evoked events before and 1 second after the whisker stimulation. The difference 
between the two was the measure of evoked activity. The value of 0.1 Hz is 
equivalent to 1 event in 10 seconds. All values are expressed as mean + standard 
deviation. The average for antibody treated group (n=177 cells in 3 mice) was 0.03 + 
0.03 Hz, for vehicle treated group (n=255 cells in 3 mice) was 0.02 + 0.06 Hz and for 
wt control (n=132 cells in 3 mice) was 0.30 + 0.34 Hz. Statistical significance 
(p<0.05) was seen between the antibody treated and wt control and vehicle treated 
and wt control groups (Figure 5.24).  
 
Mouse Whisker Mouse Whisker Mouse Whisker 
Ab-treated 1 D2 Vehicle-treated 1 C3 Wt control 1 C3 
Ab-treated 2 D4 Vehicle-treated 2 C4 Wt control 2 C4 
Ab-treated 3 C4 Vehicle-treated 3 C2 Wt control 3 C3 
 
Table 5.2: List of animals and whiskers stimulated 
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Figure 5.24: Evoked Activity. The values are mean + SD. The Y-axis represents Hz. The average 
for antibody treated group (n=177 cells) was 0.0292 + 0.009, for vehicle treated group (n=255 
cells) was 0.0216 + 0.001 and for wt control (n=132 cells) was 0.2311 + 0.029. Statistical 
significance (p<0.05) was seen between the antibody treated and wt control and vehicle treated and 
wt control groups.  
Statistical significance (p<0.05) was seen between the antibody treated and wt control and vehicle 
treated and wt control groups.  
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The chronic imaging of the same cells was done and comparisons made over 8 weeks. 
The first imaging session was considered as baseline value and weekly measurements 
were made in three groups. The table 5.3 below shows values for each group. The 
values are expressed as mean + standard deviation. All the mice in wt control died 
after 5 weeks of imaging. 
 
The wt control animals had higher evoked activity at the baseline and continued to 
have higher activity than transgenic groups (Ab-treated and vehicle treated). The 
evoked activity in both transgenic groups followed a similar trend (Figure 5.26). 
There was significant statistical difference between wt control and transgenic group at  
all the time points except at 3rd week. However, the statistical significance seen 
between antibody treated and vehicle treated transgenic groups. The linear regression 
analysis shows that response of wt control is different to that of Ab-treated and 
vehicle-treated groups (Figure 5.26).  Thus, the data proves that longitudinal imaging 
B 
Figure 5.25: Sample Evoked Activity. A.  Each trace represents activity of individual cells from an 
Ab-treated mouse. The grey lines indicate whisker stimulation and black tick marks indicate 
events. Most of the evoked activity is after whisker stimulation. B. Whisker stimulated activity of a 
single cell in an Ab-treated mouse. Time zero indicated the time of whisker stimulation 
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of calcium transients in the same population of cells is feasible. Our data show that 
the transgenic mice differ from wt control mice with respect to whisker-evoked 
response. However, our immunotherapy showed only a slight trend of trend in 
recovery of neuronal activity in response to immunotherapy. This trend should be 
further examined in larger animal groups and under even better controlled conditions.  
 
 Ab-treated Vehicle-treated Wt control 
Baseline 0.03 + 0.06 0.11 + 0.24 0.15 + 0.24 
1 week 0.02 + 0.07 0.02 + 0.07 0.30 + 0.53 
2 weeks 0.06 + 0.07 0.03+ 0.12 0.28 + 0.51 
3 weeks 0.06 + 0.10 0.07 + 0.22 0.22 + 0.43 
4 weeks 0.05 + 0.08 0.04 + 0.18 0.17 + 0.18 
5 weeks 0.03 + 0.08 0.02 + 0.07 0.20 + 0.20 
6 weeks 0.04 + 0.07 0.003 + 0.07  
7 weeks 0.03 + 0.08 0.01 + 0.06  
8 weeks 0.014 + 0.09 0.004 + 0.05  
 
Table 5.3: Evoked Response of Ab-treated, vehicle-treated and wt control over weeks. The values are 
mean + SD in units of Hz. 
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Figure 5.26: Evoked Activity over weeks. The values are mean + SD. The Y-axis represents Hz. 
Statistical significance (p<0.05) is seen between antibody treated and wt control (red stars) at 
baseline, 1 wk, 2 wk, 3 wk, 4wk and 5 wk; between vehicle treated and wt control groups (green 
stars) at 1 wk, 2 wk, 3 wk, 4 wk and 5 wk; between Ab-treated and vehicle treated (blue stars) at 
baseline, 2 wk, 6 wk and 7 wk. The dashed lines represent the linear regression for the time points.  
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5.3.5 Neuropil activity 	  
Neuropil is the milieu in which the neuronal networks function. It has been shown 
that whisker-stimulation elicited clear calcium transients not only in neuronal somata 
but also in the neuropil (Lutcke, et al. 2010). Therefore, we measure the neuropil 
activity as well. The neuropil activity was measured in all the three groups and it was 
similar to evoked activity measurement. We quantified the rate of evoked events 
before and 1 second after the whisker stimulation. The difference between the two 
was the measure of evoked activity. The value of 0.1 Hz is equivalent to 1 event in 10 
seconds. All values are expressed as mean + standard deviation. The average for 
antibody treated group (n=177 cells) was 0.19 + 0.23 Hz, for vehicle treated group 
(n=255 cells in 3 mice) was 0.06 + 0.22 Hz and for wt control (n=132 cells in 3 mice) 
was 0.13 + 0.23 Hz. Statistical significance (p<0.05) was seen between the antibody 
treated and wt control and vehicle treated and wt control groups (Figure 5.27).  
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Figure 5.27: Neuropil Activity. The values are mean + SD. The Y-axis represents Hz. Statistical 
significance (p<0.05) was seen between antibody treated and wt control; and between vehicle 
treated and wt control groups.  
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The chronic imaging of the same cells was done and comparisons made over 8 weeks. 
The first imaging session was considered as baseline value and weekly measurements 
were made in three groups. The table below shows values for each group. The values 
are expressed as mean + standard deviation. 
 
The neuropil response of cells over weeks shows similar trend as whisker evoked 
activity. The neuropil activity of wt control decreased over 5 weeks and activity of 
Ab-treated and vehicle treated follows similar trend (Figure 5.29). 
 
 
 
 
10%
%
D
R
R
Figure 5.28: Sample Neuropil Activity. A. Trace represents neuropil activity of one imaging spot. 
The grey lines indicate whisker stimulation. Most of the evoked activity is after whisker stimulation. 
B. Whisker stimulated neuropil activity of one imaging spot. Time 0 indicated the time of whisker 
stimulation 
A 
B 
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 Ab-treated Vehicle-treated Wt control 
Baseline 0.18+ 0.20 0.29 + 0.64 0.77 + 0.81 
1 week 0.23 + 0.40 0.14 + 0.21 1.37 + 1.48 
2 weeks 0.39 + 0.36 0.16 + 0.20 1.41 + 1.46 
3 weeks 0.47 + 0.34 0.07 + 0.22 1.06 + 1.24 
4 weeks 0.26 + 0.28 0.07 + 0.16 0.22 + 0.31 
5 weeks -0.03 + 0.17 -0.03 + 0.09 0.83 + 0.35 
6 weeks 0.10 + 0.14 -0.03 + 0.09  
7 weeks 0.07 + 0.32 0.01 + 0.04  
8 weeks 0.003 + 0.10 0.03 + 0.10  
 
 
	  
Thus, we successfully used YC3.60 in pre-plaque phase of APPswe mice to measure 
neuronal activity in the barrel cortex. We measured the spontaneous activity, whisker-
evoked response and neuropil response in these mice over period of 8 weeks and 
noted differences in wt control and transgenic mice.  
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Figure 5.29: Neuropil activity over weeks. The values are mean + SD. The Y-axis represents Hz. 
Statistical significance is seen between the antibody treated and vehicle treated; between antibody 
treated and wt control; and between vehicle treated and wt control groups.  
Table 5.4: Neuropil activity  of Ab-treated, vehicle-treated and wt control over weeks. The values 
are mean + SD in units of Hz. 
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5.3.6 Immunohistochemistry 
 
After the completion of long term imaging experiments, the mice were sacrificed and 
brain was sectioned (see section 4.2.8). We wanted to confirm the area of virus 
injection, confirm neuronal labeling and how these neurons would be different in 
transgenic mice structurally. We also wanted to examine sections for presence of 
beta-amyloid plaques.  
 
The floating sections showed viral expression of YC3.60 in the cortex and axonal 
projections in the white matter (Figure 5.30), which is consistent with published 
reports (Lutcke, et al. 2010). Beta-amyloid plaques stained by 6E10 are seen in the 
neocortex of 24-month old APPsweArc mice injected with YC3.60 (Figure 5.30 A) 
and not in 10-month old APPswe mice (Figure 5.30 B). 
 
 
 
The YC3.60 co-localized with NeuN. The YC3.60 labels only a percentage of 
neuronal population (Figure 5.31). 
 
 
 
 
 
 
 
250 um  500 um  
A B
Figure 5.30: Viral Expression in cortex A. 24-month old APPsweArc mouse showing YC3.60 
expression and beta-amyloid plaques. B. 10-month old APPswe mousing showing YC3.60 
expression but no beta-amyloid plaques. 
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The in vivo imaging of transgenic animals over weeks did not reveal development of 
any plaques in the imaging areas. However, immunohistochemistry showed beta-
amyloid plaques in cortex of both Ab-treated and vehicle-treated animals (Figure 
5.32). These mice were around 10 month of age at the time of immunohistochemistry. 
Ab-treated mice had 4-6 beta-amyloid plaques in the cortex whereas vehicle treated 
mice had 8-10 beta-amyloid plaques. This is the beginning of plaques deposition in 
APPswe mice (Hsiao, et al. 1996). 
 
 
 
 
 
250 um  50 um  
A B
500 um  
A
250 um  
B
Figure 5.31: YC3.60 and NeuN co-localization A. 10-month old APPswe mouse showing co-
localization of YC3.60 and NeuN. B. 63x magnified confocal image. Red: NeuN, Green: YC3.60 
Figure 5.32: Development of amyloid plaques A. Ab-treated 10-month old APPswe mouse 
showing beta-amyloid plaques. B. Vehicle-treated 10-month old APPswe mouse showing beta-
amyloid plaques.	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YC3.60 expression under CAG promoter labeled both neuronal bodies and dendrites 
(Figure 5.33). The 24-month old APPsweArc mice showed dystrophic neurites 
(arrows) whereas 10-month old APPswe mice did not show any (Figure 5.34 A and 
B). 
 
 
 
 
On zooming in the 24-month old APPswe mice showed dystrophic neurites and 
atrophic neuronal bodies in the periphery of beta-amyloid plaques (Figure 5.34 A and 
B).  
 
 
 
Figure 5.34: Zoomed in dystrophic neurites in 24-month old APPsweArc mouse, shown by arrow and 
atrophic neuron, shown by arrow head.  Red: beta-amyloid plaques, Green: YC3.60 
 
 
With the technique of immunohistochemistry, we were able to confirm the area of 
virus injection, confirm neuronal labeling and observe beginning of plaque deposition 
250 um  50 um  
250 um  125 um  
A B
50 um  50 um  
A B
Figure 5.33: Dystrophic neurites A. 10-month old APPswe mouse did not show any dystrophic 
neurites. B. 24-month old APPsweArc mouse showing dystrophic neuritis (arrows).	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in the mice, which were in pre-plaque phase during long-term imaging. Furthermore, 
we were able to identify dystrophic neurites and atrophic in old APPswe mice injected 
with YC3.60. These immunohistochemistry results were complementary to the 
functional imaging data.  
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6.1 Standardization of chronic imaging protocols 	  
Chronic observation and manipulation of cells in the cortex is integral part of studies 
on neurons, glia and microvasculature. The discovery of 2PM was a landmark in the 
field of chronic imaging (Svoboda, et al. 1997). However, main principles for chronic 
imaging preparation are stability by reducing motion artifacts, tolerance of the animal, 
and maintenance of optical quality over weeks, and reproducibility. Without 
optimizations of these key factors, chronic imaging is not possible. 
 
There have been several reports where head posts were used for chronic imaging  
(Burgold, et al. 2011, Busche, et al. 2008, Hefendehl, et al. 2011). Custom-made head 
posts were used in this dissertation work (Figure 5.1), which were very well tolerated 
for several weeks by the animal. The aluminum used to make these head posts was 
important key in decreasing the weight. Here, we show that the head posts reduce the 
motion artifacts to acceptable low levels and provide steady images for time-lapse 
imaging and calcium imaging (Figure 5.2 and 5.3).  
 
Even as the debate for optimum window for chronic imaging continues, we used 
craniotomy for the simplicity of technique and wide area available for imaging 
purposes. Thinned-skull preparations are shown to cause less microglia and astrocyte 
reaction in the imaging area and affect dendritic turnover (Drew, et al. 2010, 
Grutzendler and Gan 2006, Xu, et al. 2007). Xu et al. reported that effects of 
craniotomy on spine dynamics subsided by 2 months. Most of the studies involving 
imaging of AD animal models have used craniotomy (Bacskai, et al. 2001, Bolmont, 
et al. 2008, Burgold, et al. 2011, Busche, et al. 2008, Hefendehl, et al. 2011). The 
optimized procedures used here for preparation of the chronic window had success 
rate of 60-70% for ‘clearing up’ after 3 weeks and the ‘cleared’ windows remained 
optically viable for several weeks to months (Figure 5.5).  
 
Another aspect was labeling of beta-amyloid plaques with Methoxy-X04. Several of 
the published protocols were tried but did not result in satisfactory plaque labeling 
(Figure 5.6 A). However, the protocol obtained by Prof. Bacskai, produced 
remarkable labeling of plaques (Figure 5.6 B).  We were also able to successfully 
Discussion 
	   104	  
inject the genetically encoded calcium indicator, YC3.60 in barrel cortex of APPswe 
mice and obtain satisfactory labeling of layer 2/3 neocortical neurons (Figure 5.30).  
 
6.2 Various techniques to study microglia-plaque interaction  	  
The second part of the project was the morphological aspect, which was to study 
microglia-plaque interaction. Most of the papers in the field of immunotherapy in AD 
and microglia response are done either with topical antibody application and in vivo 
imaging or systemic application with immunohistochemistry. We tried the technique 
of plaque targeted antibody application, using the principle of bulk-loading of calcium 
dyes (Garaschuk, et al. 2006). We injected the antibody under microscopic guidance 
for optimum injection near amyloid plaques. The technique caused minimal tissue 
damage (Figure 5.8). However, we could not demonstrate plaque removal in 
APP/PS1dE9 and APPsweArc mice (Figure 5.9 and 5.12). The main drawback of this 
technique was the limitation of imaging area and this would suggest that the 
concentration of antibody too low to clear plaques. We also tried the technique of 
fluorescent antibody application to track the antibody spread and uptake (Figure 
5.13). We saw that the antibody was bound to the plaque up to 7 days (Figure 5.12).  
However, even with this approach no plaque removal was seen (Figure 5.12). We 
observed similar number of microglia surrounding plaques as reported by Bolmont et 
al.  
 
The next logic was even if there is no plaque removal, there may be alteration of 
microglia dynamics. The amyloid plaques had different tiers of microglia surrounding 
and most plaques had around 5-8 microglia in each plane (Figure 5.7 and Figure 
5.13). We performed time-lapse imaging of microglia over 6-8 hours after topical 
application of anti-Aß antibody (Figure 5.14 and Figure 5.12) and PBS (Figure 16). 
The preliminary analysis of these data shows vigorous recruitment of microglia to the 
plaque periphery after topical application of anti-Aß antibody. However, more studies 
focusing of time-lapse imaging over days is needed to confirm these findings. 
 
We here presented two unique techniques, which can be used to study plaque-
microglia reactions. 
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6.3 Neocortical Neuronal Activity in Alzheimer’s Disease Animal 
Models 	  
Alzheimer’s disease is a disorder of neuronal function and biophysically speaking, it 
can be described as a failure of neuronal circuits. The various neuronal networks 
involved in cognition, memory and other higher mental functions are affected by 
neurodegenerative changes. That being said, so far there have not been many in vivo 
studies focusing on dysfunction of neuronal networks in AD. This dissertation work is 
unique in the sense that we used a genetically encoded calcium indicator to study 
spontaneous and whisker-evoked activity longitudinally in a mouse model of brain 
amyloidosis in pre-plaque phase and were able to test therapeutics such as 
immunotherapy, which so far has been missing in the field of AD.  
 
6.3.1 Expression of YC3.60 and measurement of calcium tranients 
The discovery of genetically encoded calcium indicators (Miyawaki, et al. 1997) has 
led to development of wide repertoire of these indicators (Mank and Griesbeck 2008), 
and the list is still expanding. Of all the available families of GECIs, GCaMP and 
Yellow Cameleons are most commonly used. We used calcium indicator Yellow 
Cameleon 3.60 coupled to AAV for labeling of a population of neurons. Previously it 
was shown that YC3.60 under human synapsin promoter labeled cortical neurons 
densely and was observed preferentially in Layer 2/3 and Layer 5 (Lutcke, et al. 
2010). We used 2 types of promoters h-synapsin and CAG. One goal was to 
reproduce the results of Lutcke 2010 and another was to characterize the indicator 
with CAG promoter and compare it with h-synapsin. We saw expression in L2/3 and 
L5 (Figure 5.17 and Figure 5.18) and was similar to the published reports (Lutcke, et 
al. 2010). CAG promoter resulted in extensive axonal labeling than h-synapsin 
promoter. We also confirmed the labeling by immunohistochemistry (Figure 5.30 and 
Figure 5.31). We were also able to find the same population of cells in all of the 
imaging areas in every imaging session in all the animals (Figure 5.19), which was 
very important part of chronic imaging. 
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6.3.2 Spontaneous activity in AD transgenic and wt control mice 
In vivo calcium imaging of cortical circuits in APP/PS1 AD transgenic mice has 
revealed that transgenics have a greater proportion of hyperactive and hypoactive 
neurons than nontransgenic controls (Busche, et al. 2008). This study measured only 
the spontaneous activity and did not answer the questions regarding long-term 
modulation of neuronal response to stimuli. The first study which looked at sensory-
evoked activity in AD was by Grienberger et al., which reported progressive 
deterioration of neuronal tuning for orientation of visual stimuli, which occurred in 
parallel with age-dependent increase of beta-amyloid load in visual cortex of 
APP/PS1 mice (Busche, et al. 2012).  However, both Busche, et al. 2008 and 
Grienberger, et al. 2012 used OGB-1, which is a synthetic calcium indicator with 
several short comings when it comes to longitudinal imaging (Mank and Griesbeck 
2008).   
 
In this dissertation work, we measured spontaneous response of same population of 
cells of barrel cortex. We saw statistically significant difference between the antibody 
treated and vehicle treated; between antibody treated and wt control; and between 
vehicle treated and wt control groups (Figure 5.21). The linear regression analysis 
showed that the response of antibody treated animals increased over the period of 8 
weeks and follows the trend of wt control, whereas the response of vehicle treated 
decreased over the same duration (Figure 5.23). This shows a trend towards reversal 
of the spontaneous activity of in antibody treated transgenics towards activity of 
nontransgenics. Many different anti-Aß antibodies have been used for immunotherapy 
in AD transgenics. Passive immunization in PDAPP mice with 3D6 (IgG2b Aß1-15) 
and 10D5 (IgG1 Aß3-7) antibodies clears plaques but not 16C11 (IgG1 Aß33-42) (Bard, 
et al. 2000).  Many studies used topical application of anti-Aß antibodies in AD 
transgenics and observed plaque clearance (Bacskai, et al. 2001, Prada, et al. 2007, 
Spires-Jones, et al. 2009). The antibody we used was in-house generated anti-Aβ 
IgG2a targeted against fibrillar Aβ, which has shown efficacy in plaque removal 
(Biscaro, et al. 2009).  Unlike Busche et al., we did not find cluster of hyperactive 
neurons, the baseline spontaneous activity was lower in transgenics compare to 
nontransgenic controls. This could be attributed to difference in transgenic line 
(APP/PS1 vs. APPswe), age and difference in AD pathology (plaque vs. pre-plaque 
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phase). Also, our animal group was small with n=3. Thus, more studies with larger 
animal groups are warranted.  
6.3.3 Evoked Activity in AD transgenic and wt control mice 
The recent reports indicate that neuronal activity is affected before development of 
plaques, which is mainly caused by soluble Aß species (Cheng, et al. 2007, Cleary, et 
al. 2005, Holcomb, et al. 1998, Klein, et al. 2001, Lesne, et al. 2006, Selkoe 2008, 
Shankar, et al. 2007, Shankar, et al. 2008, Tomiyama, et al. 2010, Walsh and Selkoe 
2007). Most recently, Busche, et al. 2012 looked at neuronal activity in hippocampal 
CA1 pyramidal cells of APP/PS1 mice in an in vivo setting and found selective 
increase in hyperactive neurons already before the formation of plaques, suggesting 
that soluble species of Aβ may underlie this impairment. Thus, the emphasis is now 
shifting towards study of pre-plaque pathology of AD. We selected whisker 
stimulation as a method to study evoked activity in rodent barrel cortex neuronal 
networks. The rationale being that it is a well studied system and the whisker 
stimulation protocol was already standardized in the lab. As far as we know, this is 
the first study addressing the question of sensory evoked activity in AD animal 
models using genetically encoded calcium indicators, which looked at the longitudinal 
measurement of neuronal activity paralleling the progression of AD pathology.  
 
The cumulative analysis of all the cells over 8 weeks did not show significant 
difference between antibody treated and vehicle treated transgenic groups (Figure 
5.24) but there was statistical significance (p<0.05) between transgenic and wt control 
(Figure 5.24), showing the sensitivity of the indicator in detecting changes in calcium 
transients. However, the linear regression analysis for all the 3 groups showed that the 
trend of evoked activity decreased over days (Figure 5.26). There are several 
variables like level of anesthesia, laser intensity, positioning of animal w.r.t. piezo 
stimulator, inter and intra animal differences, which can change between imaging 
sessions. We standardized most of the parameters but some inherent biological 
variable in the animal response could not be avoided. Despite these challenges, the 
inter-animal variability was low and the response was consistent.  
 
The aim at the beginning of the project was to see if there is any antibody treatment 
effect on evoked activity in transgenic animals and if it is different from wt control. 
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We chose APPswe mice for the slow development of pathology, typically starting 
around 8-10 month (Hsiao, et al. 1996), which we thought would complement the 
longitudinal measurement of evoked activity. Our results show that the transgenic 
mice have less evoked activity than wt control mice but there was no significant 
treatment effect seen between transgenics although there was trend indicating increase 
in evoked activity in antibody treated mice. The animal group was small in this study 
and more studies with larger animal groups are warranted. We prove that it is possible 
to longitudinally image neuronal activity with ongoing AD pathology. This opens the 
experimental options for further explore AD pathology in real time and correlate 
disease progression with neuronal dysfunction. It would also be interesting to image 
awake behaving AD transgenic with these protocols and study neuronal activity 
during cognitive tasks and further study how therapeutic interventions such as 
immunotherapy would modify neuronal activity. 
 
6.3.4 Neuropil Activity in AD transgenic and wt control mice 
Neuropil is the milieu in which the neuronal networks function. It has been shown 
that whisker-stimulation elicited clear calcium transients not only in neuronal somata 
but also in the neuropil (Lutcke, et al. 2010). Thus, whisker-evoked activity correlates 
to neuropil activity. Hence, we measured neuropil activity in response to whisker 
stimulation. The analysis was done in the similar fashion to that of whisker-evoked 
neuronal activity. Linear regression analysis showed that the both transgenic groups 
had similar trends and differed significantly from wt control group (Figure 5.29). 
Antibody treatment had no significant effect on neuropil activity of transgenic mice. 
The neuropil response was similar to whisker-evoked neuronal response. In other 
words, neuropil activity is an indirect measure of evoked neuronal activity. The 
further experiments would be in similar lines to study sensory evoked activity.  	  
6.3.5 Immunohistochemistry 	  
After the last imaging session, the animals were perfused and the floating sections 
were studied for plaques and YC3.60 expression. YC3.60 expression was seen in all 
the animals injected with the virus (Figure 5.30). We obtained labeling of neurons 
with h-synapsin promoter and both neurons and axons with CAG promoter. CAG 
promoter is more suitable for dendritic imaging. Both the promoters had equal success 
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rate in our hands. All the neurons labeled with YC3.60 colocalized with NeuN 
staining, proving the fidelity of expression (Figure 5.31). 
 
The animals were 6 months of age when virus was injected and 7 months of age when 
chronic imaging was started. The deposition of amyloid plaques starts at the age of 8-
10 months in APPswe mice and our initial goal was to start imaging in the pre-plaque 
pathology and visualize appearance of plaques and study response of neurons, which 
were in the plaque periphery.  But, none of the transgenic we imaged developed 
plaque in the imaging area. However, when the tissue sections were stained with 6E10 
plaques were seen in the hippocampus and cortex (Figure 5.32). There was no 
significant plaque reduction seen after antibody treatment. In other experiment, the 
24-month-old APPsweArc mice injected with YC3.60 showed drastic changes in 
neuronal morphology such as shortened, dystrophic neuritis and shrunken cell bodies 
compared to 10-month-old APPswe mice (Figure 5.33 and Figure 5.34). This shows 
that the indicator is sensitive for morphological changes too.  
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This dissertation work looked at the functional and morphological aspects of 
Alzheimer’s disease with the technique of two-photon imaging.  The first project 
involved development of different techniques to study microglia-plaque interaction. 
There were several technical difficulties involved in the project. We were able to 
show that plaque directed application of antibody could be successfully performed 
and time-lapse imaging of such animals over hours was possible. Preliminary data 
also showed recruitment of microglia to the beta-amyloid plaque periphery after 
topical application of anti-Aß antibody. 
 
The second project looked at the neocortical neuronal activity with the use of genetic 
ally encoded calcium indicator in APPswe mice who were 6 months of age (pre-
plaque phase) at the beginning of experiment. Immunotherapy was combined along 
with longitudinal imaging of neuronal network of barrel cortex using whisker 
stimulation as a sensory input. The nontransgenic wt control mice had higher evoked, 
spontaneous and neuropil activity compared to the transgenic mice. Immunotherapy 
was effective in improving the spontaneous activity in antibody treated mice but there 
was no significant increase in evoked and neuropil activity after immunization. The 
transgenic mice developed plaques in the 8 weeks of imaging and there was no 
significant difference in antibody treated and vehicle treated mice. These results 
support the hypothesis that neuronal activity is affected prior to the appearance of 
plaques. This is a first study in the direction of longitudinal imaging of neuronal 
network in AD mice. The future experiments would involve another model with faster 
appearance of plaques and increase the number of animals in each group. We had 
only 3 animals in each group. Also, there are more options of genetic encoded 
calcium indicators available (Looger and Griesbeck 2012). Another idea would be to 
use oligomeric antibodies, which are yet to be completely characterized and study 
their effect in comparison to anti-Aß antibodies. Further, these techniques could be 
used to study neuronal activity in awake, behaving mice during cognitive tasks.  
 
Overall, this dissertation was able to establish and use techniques of long term in vivo 
imaging at different stages of Alzheimer’s disease pathophysiology. These techniques 
can be further used to study different aspects ranging from neuronal activity, 
immunotherapy effects, microglia and astrocyte activities, cognitive tasks, which 
would help in better understanding of pathophysiology of Alzheimer’s disease and 
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ultimately develop effective therapeutics to help millions suffering from this 
debilitating illness.  
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9.1 Genotyping 
 
APP/PS1dE9 and APPsweArc primers: 
 
Prp-sens: 5’- CAGAACTGAACCATTTCAACCGAGC -3’ 
 
hAPPdn: 5’- TCAGTGGGTACCTCCAGCGCCCGAG- 3’ 
 
Reaction: 
2 µl   Tail lysate 
2 µl   10x PCR buffer 
0.4 µl  dNTPs (10 mM each) 
0.4 µl  Primers (20 µM) 
1 µl   Redtaq polymerase 
13.4 µl   PCR water 
 
Pipetted on ice and following cycling reaction was used. 
 
1. 95°C  2 min 
2. 94°C  30 sec 
3. 60°C  1 min  
4. 72°C  1 min go to step 2, 35 times 
5. 72°C  7 min 
6. 4°C    hold 
 
Product of PCR: about 180 bp 
 
CX3CR1 primers: 
 
oIMR3945: 5’- TTCACGTTCGGTCTGGTGGG -3’ 
oIMR3946: 5’- GGTTCCTAGTGGAGCTAGGG- 3’ 
oIMR3947: 5’- GATCACTCTCGGCATGGACG- 3’ 
 
Reaction: 
2 µl   Tail lysate 
2 µl   10x PCR buffer 
0.4 µl  dNTPs (10 mM each) 
0.6 µl  oIMR3945 (20 µM) 
0.8 µl  oIMR3946 (20 µM) 
0.6 µl  oIMR3947 (20 µM) 
1 µl   Redtaq polymerase 
12.2 µl PCR water 
  
 
 
Pipetted on ice and following cycling reaction was used. 
 
1. 95°C  3 min 
2. 94°C  30 sec 
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3. 60°C  30 sec  
4. 72°C  2 min go to step 2, 35 times 
5. 72°C  2 min 
6. 4°C   hold 
 
 
PCR products: +/+ 970 bp 
   +/- 1010 and 970 bp 
   -/- 1010 bp 
 
9.2 Score sheet 
 
SCORE SHEET FOR POST OPERATIVE EVALUATION 
 
Animal # _________________  Cage # _________________ 
Date of Operation ______________ 
Pre-operative weight _____________(g)  
Procedure _______________________________________ 
 
Date     
Day post-procedure     
Time     
TREATMENTS     
 Analgesics (substance/amount)     
EXTERNAL OBSERVATIONS     
 Activity 
0: lying 1: gets up and moves slowly 
2: active movements and exploratory 
behavior 
    
 Hair coat 
0: completely rough 1: rough and 
shiny in places 2: normal shiny 
    
 Eyes 
0: closed 1: open, red 2: Normal 
    
 Eating 
0: No 1: Yes 
    
 Drinking 
0: No 1: Yes 
    
 Feces 
0: No 1: Yes 
    
 Urine 
0: No 1: Yes 
    
PHYSICAL EXAMINATION     
      Rate & type of breathing 
0: Labored 1: Shallow/Rapid 2: 
Normal 
    
 Normal gait/paralysis 
0: not walking 1: limping/hyperactive 
2: normal gait 
    
 Fecal/urine soiling of coat 
0: Yes 1: No 
    
            Hydration     
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0: severe (no skin turgor, no urine 
output, dry mouth) 
1: moderate (dry mouth) 
2: Normally hydrated 
 Appearance 
0: wasted 1: Normal 
    
 Body weight     
       % change from pre-op weight     
 
SUTURE/STAPLES LINE 
    
 Head post 
0: lost 1: loosened 2: present 
    
 Wound edges 
0: red 1: slight erythema 2: normal 
    
 Swelling around incision 
0: visible swelling 1: slight edema  
2: normal 
    
 Swelling under incision 
0: visible swelling 1: slight bulge 
2: normal 
    
 Sutures 
0: missing 1: gaping wound 2: intact 
sutures 
    
 Exudate from incision 
0: Pus/blood 1: serous exudates 
2: no exudate 
    
Sutures/staples removed? (date)          
Total Score:  
22-32: Normal, observe next day 
15-21: Observe every 4 h and 
intervene (analgesics, antibiotics, 
hydrate, close the wound)  
Less than 15: Terminate 
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9.3 List of Animals  
 
Animal 
No/Tg Virus 
Virus 
Expression Window Quality Outcome Remarks 
1/+ CAG-YC3.60 - - Dropout  
2/- CAG-YC3.60 - - Dropout  
3/+ CAG-YC3.60 Good Clear Imaged Immunized 
4/+ CAG-YC3.60 - - Dropout  
5/+ CAG-YC3.60 - - Dropout  
6/+ CAG-YC3.60 Superficial Clear Imaged Immunized 
7/- CAG-YC3.60 Moderate Some gliosis Imaged  
8/+ CAG-YC3.60 Good Clear Imaged Non-immunized 
9/+ CAG-YC3.60 Good Clear Imaged Non-immunized 
10/- CAG-YC3.60 None gliosis Not imaged  
11/- CAG-YC3.60 Good Clear Imaged Wt Control 
12/- CAG-YC3.60 Faint Good Not imaged Weird behavior 
13/- CAG-YC3.60 Restricted gliosis Not imaged  
14/+ CAG-YC3.60 Diffuse some gliosis Not imaged Weird behavior 
21/- h-syn YC3.60 Good Clear Imaged Wt Control 
23/+ h-syn YC3.60 Good Clear Imaged Non-immunized 
24/- h-syn YC3.60 Moderate gliosis Not imaged  
25/- h-syn YC3.60 Good Clear Imaged Wt Control 
26/+ h-syn YC3.60 Good Clear Imaged Immunized 
27/- h-syn YC3.60 Superficial Gliosis Not imaged  
 
 
9.4 List of Reagents, buffers, kits and antibodies 
 
Buffer/Reagent Composition 
10x PBS 1.4 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM 
KH2PO4 
10x TBS 0.84 M Tris-HCl, 0.16 M Tris-base, 1.5 M NaCl 
TBS-T 1 x TBS, 0.05% Tween20 
Ringer solution 135 mM NaCl, 5.4 mM KCl, 5 mM Hepes, 1.8 mM CaCl2; pH 7.2 
with NaOH 
Anti-freeze 
solution 
0.5 M phosphate buffer with 30% ethylene glycol and 30% 
glycerol 
 
Kits 
1. Dylight 498 antibody labeling kit from Amersham, Switzerland 
2. Dylight 588 antibody labeling kit from Amersham, Switzerland 
 
Primary Antibodies 
1. Anti 6E10 Signet (SIG-39300) 
2. Anti GFAP Advanced ImmunoChemical Inc. (031223) 
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Secondary Antibodies 
1. Anti mouse – Cy5 Jackson Immuno-research #715-176-150 
2. Anti mouse – Cy3 Jackson Immuno-research #715-165-151 
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